"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04492475","Adaptive COVID-19 Treatment Trial 3 (ACTT-3)",,"Completed","Has Results","COVID-19","Drug: Interferon beta-1a|Other: Placebo|Drug: Remdesivir","Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6|Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 by Race|Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 by Ethnicity|Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 by Sex|Change From Baseline in Alanine Aminotransferase (ALT)|Change From Baseline in Aspartate Aminotransferase (AST)|Change From Baseline in C-reactive Protein (CRP)|Change From Baseline in Creatinine|Change From Baseline in D-dimer Concentration|Change From Baseline in Hemoglobin|Change From Baseline in Prothrombin International Normalized Ratio (INR)|Change From Baseline in Platelets|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphoctyes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Duration of Hospitalization|Duration of Invasive Mechanical Ventilation|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Duration of Non Invasive Ventilation or High Flow Oxygen Use|Duration of Oxygen Use|Number of Participants With Discontinuation or Temporary Suspension of Study Product Administration|Proportion of Participants With New Non-invasive Ventilation or High Flow Oxygen Use|Proportion of Participants With New Oxygen Use|Proportion of Participants With New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Mean Change From Baseline in the Ordinal Scale|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15 for Participants With Baseline Ordinal Score 4 and 5|Percentage of Participants Reporting Each Severity Rating on an 8 Point Ordinal Scale at Day 1|Percentage of Participants Reporting Each Severity Rating on an 8 Point Ordinal Scale at Day 3|Percentage of Participants Reporting Each Severity Rating on an 8 Point Ordinal Scale at Day 5|Percentage of Participants Reporting Each Severity Rating on an 8 Point Ordinal Scale at Day 8|Percentage of Participants Reporting Each Severity Rating on an 8 Point Ordinal Scale at Day 11|Percentage of Participants Reporting Each Severity Rating on an 8 Point Ordinal Scale at Day 15|Percentage of Participants Reporting Each Severity Rating on an 8 Point Ordinal Scale at Day 22|Percentage of Participants Reporting Each Severity Rating on an 8 Point Ordinal Scale at Day 29|14-day Participant Mortality|28-day Participant Mortality|Time to an Improvement of One Category Using an Ordinal Scale|Time to an Improvement of Two Categories Using an Ordinal Scale|Time to Discharge or to a National Early Warning Score (NEWS) of </= 2 and Maintained for 24 Hours, Whichever Occurs First|Time to Recovery for Patients With a Baseline Ordinal Score of 4 and 5","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","969","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006 ACTT-3","August 5, 2020","December 21, 2020","December 21, 2020","July 30, 2020","November 22, 2021","March 14, 2022","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Seongnam, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04492475/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04492475/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04492475/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04492475"
2,"NCT04401579","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",,"Completed","Has Results","COVID-19","Other: Placebo|Drug: Remdesivir|Drug: Baricitinib","Time to Recovery|Time to Recovery by Race|Time to Recovery by Ethnicity|Time to Recovery by Sex|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin International Normalized Ratio (INR)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Duration of Hospitalization|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Duration of Oxygen Use|Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics|Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Oxygen Use|Mean Change in the Ordinal Scale|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|14-day Participant Mortality|28-day Participant Mortality|Time to an Improvement of One Category Using an Ordinal Scale|Time to an Improvement of Two Categories Using an Ordinal Scale|Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First|Change From Baseline in C-reactive Protein (CRP)|Change From Baseline in D-dimer Concentration","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","1033","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006 ACTT-2","May 8, 2020","July 31, 2020","July 31, 2020","May 26, 2020","April 26, 2021","March 14, 2022","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Indiana University School of Medicine - Infectious Diseases, Indianapolis, Indiana, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Hospital Clinico San Carlos - Enfermedades Infecciosas, Madrid, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, City Of London, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04401579/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04401579/SAP_003.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04401579/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04401579"
3,"NCT04640168","Adaptive COVID-19 Treatment Trial 4 (ACTT-4)",,"Completed","Has Results","COVID-19","Drug: Baricitinib|Drug: Dexamethasone|Other: Placebo|Drug: Remdesivir","The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Race|The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Ethnicity|The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Sex|Change From Baseline in Alanine Aminotransferase (ALT)|Change From Baseline in Aspartate Aminotransferase (AST)|Change From Baseline in C-reactive Protein (CRP)|Change From Baseline in Creatinine|Change From Baseline in D-dimer Concentration|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin International Normalized Ratio (INR)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Days of Invasive Mechanical Ventilation / Extracorporeal Membrane Oxygenation (ECMO)|Days of Non-invasive Ventilation/High Flow Oxygen|Duration of Supplemental Oxygen Use|Desirability of Outcome Ranking (DOOR) at Day 15|Desirability of Outcome Ranking (DOOR) at Day 29|Duration of Hospitalization|Number of Participants With Discontinuation or Temporary Suspension of Study Product Administration|14-day Participant Mortality|28-day Participant Mortality|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|Percentage of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories|The Proportion of Participants Not Meeting Criteria for One of the Three Most Severe Ordinal Scale Categories at Any Time.|Time to an Improvement of One Category From Baseline Using an Ordinal Scale|Time to an Improvement of Two Categories From Baseline Using an Ordinal Scale|Time to Recovery","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","1010","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006 ACTT-4","December 2, 2020","May 18, 2021","June 18, 2021","November 23, 2020","June 28, 2022","June 28, 2022","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Kaiser Permanente San Diego Medical Center, San Diego, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|VA Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|Tulane University - Section of Pulmonary Diseases, Critical Care, and Environmental Medicine, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Michigan - Infectious Disease Clinic at Taubman Center, Ann Arbor, Michigan, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|CHI Health Creighton University Medical Center - Bergan Mercy - Pulmonary Medicine, Omaha, Nebraska, United States|Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|University of Oklahoma Health Science Center - Surgery, Oklahoma City, Oklahoma, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|Tokyo Medical and Dental University - Medical Hospital - Department of Respiratory Medicine, Tokyo, Japan|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National University Health System - Alexandra Hospital - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases, Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04640168/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04640168/SAP_003.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04640168/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04640168"
4,"NCT04542694","Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19",,"Completed","Has Results","COVID-19","Drug: Favipiravir|Drug: Standard of care","Rate of Clinical Status Improvement|Time to Clinical Improvement|Rate of Viral Elimination by Day 10|Time Before the End of Fever|Change in the Level of Lung Damage According to CT|Rate of Transfer to the Intensive Care Unit|Rate of the Use of Non-invasive Lung Ventilation|Rate of the Use of Mechanical Ventilation|Mortality","Promomed, LLC","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FAV052020","May 21, 2020","August 10, 2020","August 20, 2020","September 9, 2020","November 5, 2020","November 5, 2020","State Clinical Hospital №50, Moscow, Russian Federation|Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation|City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation|Medical institute Ogarev Mordovia State university, Saransk, Russian Federation|Smolensk clinical hospital №1, Smolensk, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04542694/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04542694"
5,"NCT04280705","Adaptive COVID-19 Treatment Trial (ACTT)",,"Completed","Has Results","COVID-19","Other: Placebo|Drug: Remdesivir","Time to Recovery|Time to Recovery by Race|Time to Recovery by Ethnicity|Time to Recovery by Sex|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin Time (PT)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics|Duration of Hospitalization|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use|Percentage of Participants Requiring New Oxygen Use|Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Mean Change in the Ordinal Scale|14-day Participant Mortality|29-day Participant Mortality|Time to an Improvement by at Least One Category Using an Ordinal Scale|Time to an Improvement of at Least Two Categories Using an Ordinal Scale|Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","1062","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006","February 21, 2020","May 21, 2020","May 21, 2020","February 21, 2020","September 25, 2020","March 14, 2022","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases, Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04280705"
6,"NCT04350593","Dapagliflozin in Respiratory Failure in Patients With COVID-19","DARE-19","Completed","Has Results","COVID-19","Drug: Dapagliflozin 10 milligram (mg)|Drug: Placebo","Prevention of COVID-19 Complications or Death: During the 30-day Treatment Period, Time to First Occurrence of New/Worsened Organ Dysfunction During Index Hospitalization or Death From Any Cause.|Improving Clinical Recovery: Hierarchical Composite Outcome Measure Including Death From Any Cause Through Day 30, New/Worsened Organ Dysfunction, Clinical Status at Day 30 and Hospital Discharge Before Day 30 and Alive at Day 30.|Time to Hospital Discharge|Total Number of Days Alive and Free From Respiratory Decompensation Requiring Initiation of Mechanical Ventilation (Includes Invasive or Non-invasive Ventilation, CPAP, or BiPAP)|Total Number of Days Alive, Not in the ICU, and Free From Respiratory Decompensation Requiring Initiation of Mechanical Ventilation (Includes Invasive or Non-invasive Ventilation, CPAP, or BiPAP)|Time to Composite of Acute Kidney Injury or Initiation of Renal Replacement Therapy, or Death From Any Cause|Time to Death From Any Cause","Saint Luke's Health System|Saint Luke's Hospital of Kansas City|AstraZeneca|George Clinical Pty Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 3","1250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00081|ESR-20-20653","April 22, 2020","March 31, 2021","June 11, 2021","April 17, 2020","April 13, 2022","June 10, 2022","Heart Group of the Eastern Shore, Fairhope, Alabama, United States|Baptist Hospital of Miami, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University, Maywood, Illinois, United States|Ascension - St. Vincent, Indianapolis, Indiana, United States|Lahey Health, Burlington, Massachusetts, United States|McLaren Health Care, Auburn Hills, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|St. Francis Hospital, Roslyn, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Clinical Trials Network of Tennessee, Memphis, Tennessee, United States|DHR Health Institute for Research and Development, Edinburg, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Sentara Healthcare, Norfolk, Virginia, United States|Clínica de Especialidades Villa María, Villa María, Province Of Córdoba, Argentina|Fundación Favaloro, Buenos Aires, Argentina|Hospital Español, Buenos Aires, Argentina|Hospital Fernández, Buenos Aires, Argentina|Hospital Pirovano, Buenos Aires, Argentina|Hospital Santojanni, Buenos Aires, Argentina|Sanatorio Anchorena, Buenos Aires, Argentina|Sanatorio Güemes, Buenos Aires, Argentina|Clínica Vélez Sarsfield, Córdoba, Argentina|Hospital San Roque, Córdoba, Argentina|Sanatorio Privado Duarte Quiros de Clinica Colombo S.A., Córdoba, Argentina|Centro de Pesquisa Dr. Marco Mota, Maceió, Alagoas, Brazil|Hospital EMEC e Hospital da Cidade, Feira de Santana, Bahia, Brazil|Hospital e Clínica São Roque, Ipiaú, Bahia, Brazil|Hospital Regional Deputado Luis Eduardo Magalhães, Porto Seguro, Bahia, Brazil|Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Unimed de Fortaleza, Fortaleza, Ceará, Brazil|Hospital de Messejana Dr Carlos Alberto Studart Gomes, Fortaleza, Ceará, Brazil|Hospital Coração do Brasil, Brasília, Distrito Federal, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, Espírito Santo, Brazil|Liga de Hipertensão Arterial, Goiania, Goias, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Gerais, Brazil|Hospital São Domingos - Unimed Uberaba, Uberaba, Minas Gerais, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Mãe de Deus, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital São José - Criciúma, Criciuma, Santa Catarina, Brazil|IPEMI- Instituto de Pesquisas Médicas de Itajaí, Itajai, Santa Catarina, Brazil|Hospital Municipal São José, Joinville, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Centro de Pesquisa Clínica do Coração, Aracaju, Sergipe, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, São Paulo, Brazil|Unimed Ribeirao Preto, Ribeirão Preto, São Paulo, Brazil|Fundação do ABC (Hospital Estadual Mário Covas), Santo André, São Paulo, Brazil|Centro Integrado de Pesquisas, São José do Rio Preto, São Paulo, Brazil|Santa Casa de Votuporanga, Votuporanga, São Paulo, Brazil|Fundação Pio XII, Barretos, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|InCor - Instituto do Coração do Hospital das Clínicas FMUSP, São Paulo, Brazil|Halton Healthcare Services, Oakville, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|CIMS Hospital Pvt. Ltd, Sola, Ahmedabad, India|MIOT International Hospitals, Manapakkam, Chennai-89, India|All India Institute of Medical Science, New Delhi, Delhi, India|Sanjivani Super Speciality Hospital Pvt Ltd, Ahmedabad, Gujarat, India|Lokmanya Tilak General Hospital, Mumbai, Maharashtra, India|Max Smart Super Speciality Hospital, Saket, New Delhi, India|Max Super Speciality Hospital (A unit of Devki Devi Foundation), Saket, New Delhi, India|Dayanand Medical College & Hospital, Ludhiāna, Punjab, India|Hospital del Prado, Acapulco, Mexico|Icaro Investigaciones en Medicina, Chihuahua, Mexico|HG de Cuernavaca Dr. Jose G Parres, Cuernavaca, Mexico|JM Research, Cuernavaca, Mexico|Instituto de Investigaciones Aplicadas a la Neurosciencias, Durango, Mexico|Antiguo Hospital Civil de Guadalajara ""Fray Antonio Alcade"", Guadalajara, Mexico|Hospital San Javier, Guadalajara, Mexico|Invesclinic MX, Guanajuato, Mexico|CIMEZAP, Jalisco, Mexico|Hospital Medica Sur, Mexico City, Mexico|Hospital Clinica Nova, Monterrey, Mexico|Hospital San Jose TEC Salud, Monterrey, Mexico|ECI Estudios Clinicos Internacionales, Puebla, Mexico|Hospital SMIQ, Queretaro, Mexico|Investigacion Medica Sonora, Sonora, Mexico|Sanatorio Santa Cruz de Toluca, Toluca, Mexico|Addenbrooke's Hospital, Cambridge, Cb2 0qq, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04350593/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04350593/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04350593"
7,"NCT04646109","Ivermectin for Severe COVID-19 Management",,"Completed","Has Results","COVID-19","Drug: Ivermectin","Gender Distribution of the Patients|Age Distribution of the Patients|Percentage of Patients With Accompanying Diseases|Percentage of Patients With Baseline Clinical Symptoms|Body Temperature Means of the Patients|Heart Rate Means of the Patients|Respiratory Rate Means of the Patients|Systolic and Diastolic Pressure Means of the Patients|Number of Participants With Clinical Response|Changes in Oxygen Saturation (SpO2) Values|Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)|Changes in Serum Lymphocyte Counts|Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)|Changes in Serum Ferritin Levels|Changes in Serum D-dimer Levels|Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism|Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Mortality|Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity","Afyonkarahisar Health Sciences University|NeuTec Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","66","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVMC_03","May 11, 2020","September 2, 2020","September 2, 2020","November 27, 2020","January 27, 2021","January 27, 2021","Afyonkarahisar Health Science University, Afyonkarahisar, Turkey|Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey|Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Turkey|Haydarpasa Sultan Abdulhamid Han Training and Research Hospital, İstanbul, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT04646109"
8,"NCT04377620","Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",,"Terminated","Has Results","COVID-19","Drug: Placebo|Drug: Ruxolitinib","Percentage of Participants Who Have Died Due to Any Cause|Number of Ventilator Free Days|Number of ICU Free Days|Oxygen Free Days|Vasopressor Free Days|Hospital Free Days|Percentage of Participants With at Least 2-point Improvement in the COVID-19 Ordinal Scale|Percentage of Participants With at Least 1-point Improvement in the COVID-19 Ordinal Scale|Time to Improvement From Baseline Category to Earliest 1-point Improvement in the COVID-19 Ordinal Scale|Percentage of Participants With the COVID-19 Ordinal Scale Reported|Change in the COVID-19 9-point Ordinal Scale|Change in SOFA Score|Number and Percentage of Participants With Treatment-related Side Effects and Serious Adverse Events","Incyte Corporation","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","211","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","INCB 18424-369","May 24, 2020","February 26, 2021","February 26, 2021","May 6, 2020","January 19, 2022","January 19, 2022","Honor Health Research Institute, Scottsdale, Arizona, United States|Sharp Memorial Hospital, San Diego, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Teradan Clinical Trials, Brandon, Florida, United States|University of Florida, Gainesville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Northshore University Health System, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Healthpartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|Mercy Research, Springfield, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Njms Clinical Research Unit, Newark, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Kettering Cancer Care, Dayton, Ohio, United States|Jefferson University Hospitals, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Allegheny Health Network, Wexford, Pennsylvania, United States|St David'S Medical Center, Austin, Texas, United States|University of Texas Health Science Center At Houston - McGovern Medical School, Houston, Texas, United States|University of Texas Health Science Cente, San Antonio, Texas, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Aurora Research Institute, Milwaukee, Wisconsin, United States|Sbih City Hospital 15, Saint Petersburg, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT04377620/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT04377620/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04377620"
9,"NCT04421027","A Study of Baricitinib (LY3009104) in Participants With COVID-19","COV-BARRIER","Completed","Has Results","COVID-19","Drug: Baricitinib|Drug: Placebo","Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])|Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 2|Percentage of Participants With at Least 1-Point Improvement on National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) or Live Discharge From Hospital|Number of Ventilator-Free Days|Time to Recovery|Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 4|Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 7|Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 10|Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 14|Duration of Hospitalization|Percentage of Participants With a Change in Oxygen Saturation From < 94% to ≥ 94% From Baseline|Overall Mortality|Duration of Stay in the Intensive Care Unit (ICU) in Days|Time to Clinical Deterioration (One-category Increase on the NIAID-OS)|Time to Resolution of Fever in Participants With Fever at Baseline|Mean Change From Baseline on the National Early Warning Score (NEWS)|Time to Definitive Extubation|Time to Independence From Non-Invasive Mechanical Ventilation|Time to Independence From Oxygen Therapy in Days|Number of Days With Supplemental Oxygen Use|Number of Days of Resting Respiratory Rate <24 Breaths Per Minute","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1525","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17830|I4V-MC-KHAA|2020-001517-21","June 12, 2020","February 12, 2021","June 10, 2021","June 9, 2020","March 24, 2022","June 2, 2022","Dignity Health Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Valleywise Health, Phoenix, Arizona, United States|St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Westchester General Hospital, Miami, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|South Shore Hospital, Weymouth, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Renown Regional Med. Center, Reno, Nevada, United States|SUNY Downstate, Brooklyn, New York, United States|East Carolina University, Greenville, North Carolina, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States|Swedish Medical Center, Seattle, Washington, United States|MultiCare Good Samaritan Hospital, Tacoma, Washington, United States|Sanatorio Sagrado Corazón, Ciudad de Buenos Aires, AR, Argentina|ClÃ-nica Zabala, Ciudad de Buenos Aires, AR, Argentina|Hospital Z.G.A.D ""Evita Pueblo"", Berazategui, Buenos Aires, Argentina|Sanatorio de la Trinidad Mitre, Caba, Buenos Aires, Argentina|Fundacion Sanatorio Guemes, Caba, Buenos Aires, Argentina|Casa Hospital San Juan de Dios, Ramos Mejía, Buenos Aires, Argentina|Hospital Interzonal General de Agudos ""Eva Peron"", San Martin, Buenos Aires, Argentina|Clinica Adventista Belgrano, Caba, Ciudad Autónoma De Buenos Aire, Argentina|Clinica Central S.A., Villa Regina, Rio Negro, Argentina|Clinica Viedma, Viedma, Río Negro, Argentina|Hospital San Roque, Cordoba, Argentina|Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Centro Hospitalar de Reabilitacao Ana Carolina Moura Xavier, Curitiba, Parana, Brazil|CEPETI Centro de Ensino e Pesquisa em Terapia Intensiva, Curitiba, Paraná, Brazil|CPCLIN, Natal, Rio Grande Do Norte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Carlos Fernando Malzoni Matao, Matao, Sao Paulo, Brazil|Pesquisare, Santo Andre, Sao Paulo, Brazil|Praxis Pesquisa Medica, Santo André, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP, Botucatu, São Paulo, Brazil|IPECC - Instituto de Pesquisa Clinica de Campinas, Campinas, São Paulo, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|CECIP - Centro de Estudos do Interior Paulista, Jaú, São Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clinicos EPP Ltda, São Bernardo do Campo, São Paulo, Brazil|Real e Benemerita Associação Portuguesa de Beneficiencia, São Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Casa de Saude Santa Marcelina - Centro de Pesquisa Clinica, São Paulo, Brazil|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Unity Hospital, Surat, Gujarat, India|Medanta-The Medicity, Gurgaon, Haryana, India|Government Medical College (GMC) Aurangabad, Aurangabad, Maharashtra, India|Government Medical College, Nagpur, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Medica Superspecialty Hospital, Kolkata, West Bengal, India|Aakash Healthcare Super Speciality Hospital, New Delhi, India|INMI Lazzaro Spallanzani, Roma, Rome, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|Nuovo Ospedale di Prato S. Stefano, Prato, Italy|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Edogawa Medicare Hospital, Edagawa, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Seoul, Korea, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, DF, Mexico|Instituto Nacional de Cancerologia, Mexico City, FD, Mexico|Instituto Nacional de Ciencias Medicas y Nutrici Salva Zubir, Mexico City, Federal District, Mexico|Hospital General Agustín O'Horán, Yucatan, Merida, Mexico|ITESM Campus Monterrey, Monterrey, Nuevo Leon, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo León, Mexico|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|City Clinical Hospital #15 named after O.M. Filatov, Moscow, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, Russian Federation|Saint-Petersburg City Pokrovskaya Hospital, Saint-Petersburg, Russian Federation|Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitario Infanta Leonor-INTERNAL MED, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|The Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Barnet Hospital, Barnet, Herts, United Kingdom|St. George's University Hospitals NHS Foundation Trust, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT04421027/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT04421027/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04421027"
10,"NCT04590586","Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","COMMUNITY","Completed","Has Results","COVID-19","Drug: Standard of care|Drug: Apremilast|Drug: Apremilast placebo|Drug: Lanadelumab|Drug: Lanadelumab placebo|Drug: Zilucoplan|Drug: Zilucoplan placebo","Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29|Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29|Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29|Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29|Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29|Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29|Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29|Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29|Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29|Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29|Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29|Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery|Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29|Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29|Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29|Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29|Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29|Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29|Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29|Apremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29|Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery|Apremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29|Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29|Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29|Zilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29|Zilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29|Zilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29|Zilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29|Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29|Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery|Zilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","515","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COV-01","November 24, 2020","August 3, 2021","August 3, 2021","October 19, 2020","June 29, 2022","June 29, 2022","Pinnacle Research Group LLC, Anniston, Alabama, United States|Good Samaritan Hospital, Bakersfield, California, United States|Sharp Chula Vista Medical Center, Chula Vista, California, United States|El Centro Regional Medical Center, El Centro, California, United States|University of California Irvine Medical Center, Orange, California, United States|Riverside Community Hospital, Riverside, California, United States|National Institute of Clinical Research, S. El Monte, California, United States|University of California Davis Health System, Sacramento, California, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Memorial Hospital Jacksonville, Jacksonville, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|The University of Iowa, Iowa City, Iowa, United States|Harper University Hospital, Detroit, Michigan, United States|Sinai Grace Hospital, Detroit, Michigan, United States|Detroit Receiving Hospital, Royal Oak, Michigan, United States|University of Tennessee Health Sciences Center, Memphis, Tennessee, United States|Medical City Ft. Worth, Fort Worth, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Texoma Medical Center, Sherman, Texas, United States|MultiCare Health System Institute for Research and Innovation, Tacoma, Washington, United States|Hospital San Juan de Dios, Ramos Mejia, Buenos Aires, Argentina|Hospital General de Agudos Dr. J. M. Ramos Mejia, Ciudad Autonoma Buenos Aires, Argentina|Hospital General de Agudos Dr. Ignacio Pirovano, Ciudad Autonoma Buenos Aires, Argentina|Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires, Argentina|Hospital Italiano de Rosario, Rosario, Argentina|Chronos Pesquisa Clinica, Brasília, Distrito Federal, Brazil|HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Goiás, Brazil|Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu, Botucatu, Sao Paulo, Brazil|Praxis Pesquisa Médica, Santo André, Sao Paulo, Brazil|Hospital Base Osorno, Osorno, Chile|Hospital General de Tijuana, Tijuana, Baja California Norte, Mexico|Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico|Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico|Hospital Civil de Culiacan, Culiacán, Sinaloa, Mexico|TSBIH ""Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich, Krasnoyarsk, Russian Federation|SBIH of Moscow ""Infectious Clinical Hospital # 1 of Department of Healthcare of Moscow"", Moscow, Russian Federation|SPb SBIH ""Alexandrovskaya City Hospital"", Saint Petersburg, Russian Federation|St-George Hospital, Saint Petersburg, Russian Federation|SPb SBIH ""Nikolaevskaya Hospital"", Saint Petersburg, Russian Federation|SPb SBIH ""City Pokrovskaya Hospital"", Saint Petersburg, Russian Federation|SPb SBIH ""City Hospital # 40 of Kurortnyi region"", Sestroretsk, Russian Federation|Nelson Mandela Academic Clinical Research Unit (NeMACRU), Mthatha, Eastern Cape, South Africa|Johese Clinical Research: Unitas, Centurion, Gauteng, South Africa|MERC SiReN, Johannesburg, Gauteng, South Africa|Drs Sarvan and Moodley, Durban, KwaZulu-Natal, South Africa|Tread Research, Cape Town, Western Cape, South Africa|Tiervlei Trial Centre, Cape Town, Western Cape, South Africa|2 Military Hospital Internal Medicine, Cape Town, Western Cape, South Africa|Dr JM Engelbrecht Trial Site, Somerset West, Western Cape, South Africa|Clinical Projects Research SA (PTY) LTD, Worcester, Western Cape, South Africa|Communal Noncommercial Profit ""Clinical City Hospital 16 of Dnipro Regional Council"", Dnipro, Ukraine|CNE of Kharkov RC Reg Cl Infectious Hospital, Kharkiv, Ukraine|Communal Non-Commercial Medical Enterprise ""O.T.Bohayevskyi Kremenchuk City Hospital #1"", Kremenchuk, Ukraine|City Clinical infectious Hospital, Odesa, Ukraine|Municipal Non-Profit Enterprise Central City Hospital Of Rivne City Council, Rivne, Ukraine|CCH #1 Vinnytsia M.I.Pyrogov NMU Ch of Infectious Diseases, Vinnytsia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT04590586/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT04590586/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04590586"
11,"NCT04348656","CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","CONCOR-1","Terminated","Has Results","COVID-19","Biological: Convalescent plasma","Number of Participants Who Were Intubated or Died|Time to Intubation or In-hospital Death|Ventilator-free Days by Day 30|Death by Day 30|Length of Stay in Intensive Care Unit (ICU)|Need for Renal Replacement Therapy|Need for Extracorporeal Membrane Oxygenation (ECMO)|Development of Myocarditis|In-hospital Death|Time to In-hospital Death|Length of Stay in Hospital|Number of Participants With Grade 3 and 4 Serious Adverse Events|Number of Participants With CCP Transfusion-associated Adverse Events (AE)|Number of Participants With Grade 3, 4, or 5 Serious Adverse Events|Patient Reported Outcome Using Change in EQ-5D-5L Score|Patient Reported Outcome- Quality-adjusted Life Days|Cost of Intervention and Hospital Stay","Hamilton Health Sciences Corporation|Canadian Blood Services|Héma-Québec|University of Toronto|Université de Montréal|Weill Medical College of Cornell University|New York Blood Center|McMaster University","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","940","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONCOR-1","March 14, 2020","March 5, 2021","June 16, 2021","April 16, 2020","March 3, 2022","March 3, 2022","Brooklyn Hospital, Brooklyn, New York, United States|Lower Manhattan Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Hospital Universitário Antônio Pedro (HUAP), Niterói, Brazil|Hemario, Rio De Janeiro, Brazil|Peter Lougheed Center, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|University of Alberta - Royal Alexandra Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Sturgeon Community Hospital, St. Albert, Alberta, Canada|Fraser Health Authority - Abbotsford Regional Hospital and Cancer Centre, Abbotsford, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|Vitalité Health Network - Acadie-Bathurst, Bathurst, New Brunswick, Canada|Vitalité Health Network - Restigouche, Campbellton, New Brunswick, Canada|Vitalité Health Network- Northwest, Edmundston, New Brunswick, Canada|Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada|Lakeridge Health Ajax Pickering, Ajax, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners - Mississauga Hospital, Mississauga, Ontario, Canada|Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada|North York General Hospital, North York, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Bluewater Health, Sarnia, Ontario, Canada|Scarborough Health Network, Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, Birchmount Hospital, Scarborough, Ontario, Canada|Niagara Health System - St. Catherines, St. Catherines, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health, St. Joseph's Health Care Centre, Toronto, Ontario, Canada|Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada|Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada|L'Hopital Chicoutimi, Chicoutimi, Quebec, Canada|Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada|Hôpital Charles-Le Moyne, Longueuil, Quebec, Canada|Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Montréal General Hospital, Montréal, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada|Centre Hospitalier Universitaire (CHU) de Québec - Université Laval, Quebec City, Quebec, Canada|Institut Universitaire de cardiologie et pneumologie de Québec, Quebec City, Quebec, Canada|Centre hospitalier régional de St-Jérôme, Saint-Jérôme, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Hôtel-Dieu, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Fleurimont, Sherbrooke, Quebec, Canada|Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|St. Paul's Hospital, Saskatoon, Saskatchewan, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04348656/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04348656/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04348656"
12,"NCT04501952","Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting",,"Terminated","Has Results","COVID-19","Drug: RDV|Drug: Placebo to Match RDV","Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 28|Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)|Percentage of Participants With COVID-19 Related Medical Visits Attended in Person by the Participant and a Health Care Professional (MAVs) or All-Cause Death by Day 28|Percentage of Participants Who Died by Day 28|Percentage of Participants With COVID-19 Related Hospitalization at Day 28|Percentage of Participants With COVID-19 Related Hospitalization or All-Cause Death by Day 14|Percentage of Participants With COVID-19 Related MAVs or All-Cause Death by Day 14|Time-Weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load From Baseline to Day 7|Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted Influenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)|Percentage of Participants With Worsening After Alleviation of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted FLU-PRO Plus Questionnaire|Percentage of Participants Who Required Oxygen Supplementation by Day 28","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","584","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-540-9012|2020-003510-12","September 18, 2020","May 6, 2021","May 6, 2021","August 6, 2020","November 16, 2021","November 16, 2021","Arizona Liver Health, Chandler, Arizona, United States|Arizona Clinical Trials, Tucson, Arizona, United States|St Joseph Hospital Eureka, Eureka, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Elevated Health, Huntington Beach, California, United States|Ruane Clinical Research Group, Los Angeles, California, United States|LA Universal Center, INC., Los Angeles, California, United States|Mills Clinical Research, Los Angeles, California, United States|Kaiser Permanente Northern California, Oakland, California, United States|FOMAT Medical Research, Oxnard, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Northern California, 6600 Bruceville Road, Sacramento, California, United States|Kaiser Permanente Northern California, 2025 Morse Ave, Sacramento, California, United States|Kaiser Permanente Northern California, 1200 El Camino Real, San Francisco, California, United States|Kaiser Permanente Northern California, 2425 Geary Blvd, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Kaiser Permanente Northern California, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Northern California, 2500 Merced St, San Leandro, California, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Premiere Medical Center of Burbank, Inc, Toluca Lake, California, United States|Kaiser Permanente Northern California, 975 Sereno Drive, Vallejo, California, United States|New Hope Research Development DBA HCD, Whittier, California, United States|Centura Health Porter Place, Denver, Colorado, United States|Nuvance Health, Danbury, Connecticut, United States|RecioMed Clinical Research Network, Boynton Beach, Florida, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Evolution Clinical Trials, Hialeah Gardens, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|L&C Professional Medical Research Institute, Miami, Florida, United States|Laguna Clinical Research Associates, Miami, Florida, United States|CTMD Research, Inc, Palm Springs, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Luminous Clinical Research - South Florida Urgent Care, Pembroke Pines, Florida, United States|St. Josephs Comprehensive Research Institute, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast, Vero Beach, Florida, United States|Triple O Research Institute PA, West Palm Beach, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Mercer University School of Medicine, Macon, Georgia, United States|Infectious Disease Associates of Kansas City, P.C.Infectious Disease Associates of Kansas City, P.C., Burr Ridge, Illinois, United States|Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States|NorthStar Medical Center, Chicago, Illinois, United States|NorthShore University Healthsystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Holy Cross Hospital, Inc., Baltimore, Maryland, United States|University of Maryland Baltimore, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|VA Boston Healthcare System, West Roxbury, Massachusetts, United States|Be Well Medical Center, Berkley, Michigan, United States|Onyx Research Institute, Flint, Michigan, United States|Memorial Hospital of Gulfport, Gulfport, Mississippi, United States|Metro Infectious Disease Consultants, Kansas City, Missouri, United States|Quality Clinical Research Inc., Omaha, Nebraska, United States|AB Clinical Trials, Las Vegas, Nevada, United States|AXCES Research Group, Santa Fe, New Mexico, United States|New York Presbyterian Hospital, Flushing, New York, United States|Northwell Health, New Hyde Park, New York, United States|Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Rosedale Infectious Diseases, Huntersville, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|Cherokee Nation WW Hastings Hospital, Tahlequah, Oklahoma, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Temple University, Philadelphia, Pennsylvania, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|University of Tennessee Health Science Center, Knoxville, Tennessee, United States|Central Texas Clinical Research, Austin, Texas, United States|UT Physicians, Bellaire, Texas, United States|Baylor University Medical Center, 700 Scott and White Dr., College Station, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Care United Research, LLC, Forney, Texas, United States|VIP Trials, Harlingen, Texas, United States|University of Texas, Houston, Texas, United States|The Crofoot Research Center, Inc, Houston, Texas, United States|Baylor University Medical Center, 1901 North McArthur Blvd, Irving, Texas, United States|Laguna Clinical Research Associates, Laredo, Texas, United States|Diagnostic Clinic of Longview - Center for Clinical Research, Longview, Texas, United States|STAAMP Research, San Antonio, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|Baylor University Medical Center, 2201 MacArthur Dr., Suite 100, Waco, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Sound Medical Research, Port Orchard, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Providence Medical Research Center, Spokane, Washington, United States|Wisconsin Corporation for Biomedical Research, Milwaukee, Wisconsin, United States|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus N, Denmark|Rigshospitalet, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom|University College Hospital, London, United Kingdom|St Mary's Hospital, London, United Kingdom|Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT04501952/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT04501952/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04501952"
13,"NCT04292899","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)",,"Completed","Has Results","COVID-19","Drug: Remdesivir|Drug: Standard of Care","Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","4891","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5773|2020-000841-15|ISRCTN15874265","March 6, 2020","April 9, 2020","June 30, 2020","March 3, 2020","December 31, 2020","December 31, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/Prot_000.pdf|""Statistical Analysis Plan: Part A"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/SAP_001.pdf|""Statistical Analysis Plan: Part B"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT04292899"
14,"NCT04377711","A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients",,"Completed","Has Results","COVID-19","Drug: Ciclesonide|Drug: Placebo","Time to Alleviation of COVID-19-related Symptoms by Day 30|Percentage of Patients With Hospital Admission or Death by Day 30|All-cause Mortality by Day 30|COVID-19-related Mortality by Day 30|Percentage of Patients With Subsequent Emergency Department Visit or Hospital Admission for Reasons Attributable to COVID-19 by Day 30|Percentage of Patients With Alleviation of COVID-19-related Symptoms Defined as Symptom-free for a Continuous Period of More Than 24 Hours (ie, Later Than 3 AM/PM Assessments) by Day 7, by Day 14, and by Day 30","Covis Pharma S.à.r.l.","All","12 Years to 100 Years   (Child, Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALV-020-001","June 8, 2020","January 5, 2021","January 5, 2021","May 6, 2020","January 6, 2022","January 11, 2022","University of Buffalo, Buffalo, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04377711/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04377711"
15,"NCT04292730","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",,"Completed","Has Results","COVID-19","Drug: Remdesivir|Drug: Standard of Care","Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5774|2020-000842-32|ISRCTN85762140","March 15, 2020","April 29, 2020","June 26, 2020","March 3, 2020","January 26, 2021","January 26, 2021","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/Prot_000.pdf|""Statistical Analysis Plan: GS-US-540-5774-appendix-16.1.9-SAP part A_f-redact"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/SAP_001.pdf|""Statistical Analysis Plan: GS-US-540-5774-appendix-16.1.9-SAP part B_f-redact"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT04292730"
16,"NCT04516746","Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",,"Active, not recruiting","Has Results","COVID-19|SARS-CoV-2","Biological: AZD1222|Biological: Placebo","Number of Participants Achieving Binary Response|Number of Participants With Adverse Events (AEs) Occurring Post Each Dose of Study Intervention|Number of Participants With Serious Adverse Events (SAE), Medically Attended Adverse Events (MAAE), and Adverse Event of Special Interest (AESI) Occurring Throughout the Study|Number of Participants With Local and Systemic Solicited AEs in the Substudy Only|Number of Participants With First Post-intervention Response for SARS-CoV-2 Nucleocapsid Antibodies Occurring Post Second Dose of Study Intervention|Number of Participants With First COVID-19 Symptomatic Illness Using Centers for Disease Control and Prevention (CDC) Criteria Occurring Post Second Dose of Study Intervention|Number of Participants With First COVID-19 Symptomatic Illness Using University of Oxford-Defined Symptom Criteria Occurring Post Second Dose of Study Intervention|Number of Participants With First Symptomatic COVID-19 Regardless of Evidence of Prior SARS-CoV-2 Infection Occurring Post Second Dose of Study Intervention|Number of Participants With COVID-19 Severe or Critical Symptomatic Illness Occurring Post Second Dose of Study Intervention|Number of Participants With COVID-19 Severe or Critical Symptomatic Illness Occurring Post First Dose of Study Intervention|Number of Participants With COVID-19-Related Emergency Department Visits Occurring Post Second Dose of Study Intervention|Geometric Mean Titers (GMTs) for SARS-CoV-2 Spike (S) and Receptor Binding Domain (RBD) Antibodies as Measured by Meso Scale Discovery (MSD) Serology Assay|Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 S and RBD Antibodies as Measured by MSD Serology Assay|Percentage of Participants With Seroresponse to the S and RBD Antigens of AZD1222 as Measured by MSD Serology Assay|GMTs for SARS-CoV-2 Neutralizing Antibodies as Measured by Pseudo-neutralization Assay|GMFR for SARS-CoV-2 Neutralizing Antibodies as Measured by Pseudo-neutralization Assay|Percentage of Participants With Seroresponse to SARS-CoV-2 Neutralizing Antibodies of AZD1222 as Measured by Pseudo-neutralization Assay|Number of Participants With COVID-19 Symptomatic Illness Occurring Post First Dose of Study Intervention","AstraZeneca|Iqvia Pty Ltd","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","32459","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8110C00001","August 28, 2020","March 5, 2021","February 14, 2023","August 18, 2020","April 1, 2022","April 1, 2022","Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Berkeley, California, United States|Research Site, El Centro, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, San Francisco, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, Coral Gables, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Fairway, Kansas, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Butte, Montana, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Berlin, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Yukon, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, North Charleston, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Spring, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Fort Belvoir, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, South Charleston, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Quillota, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Callao, Peru|Research Site, Cercado De Lima, Peru|Research Site, Lima, Peru","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT04516746/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT04516746/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04516746"
17,"NCT04498273","COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80",,"Terminated","Has Results","COVID-19","Drug: Apixaban 2.5 MG|Drug: Apixaban 5MG|Drug: Aspirin|Drug: Placebo","Hospitalization for Cardiovascular/Pulmonary Events","Frank C Sciurba|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","657","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ACTIV4-Outpatient","September 7, 2020","August 5, 2021","August 5, 2021","August 4, 2020","February 17, 2022","February 17, 2022","University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Palo Alto, California, United States|Zuckerberg San Francisco General, San Francisco, California, United States|Olive View-UCLA Medical Center, Sylmar, California, United States|Pine Ridge Family Medicine, Colorado Springs, Colorado, United States|Life Tree Health, Inc., Washington, District of Columbia, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|University of Florida at Gainesville, Gainesville, Florida, United States|Vital Pharma Research, Hialeah, Florida, United States|Advanced Research for Health Improvement, LLC, Immokalee, Florida, United States|University of Floridia at Jacksonville, Jacksonville, Florida, United States|Lakeland Regional, Lakeland, Florida, United States|Total Research Group LLC, Miami, Florida, United States|Jackson Memorial, Miami, Florida, United States|Well Pharma Medical Research, Miami, Florida, United States|Innovation Clinical Trials, Palmetto Bay, Florida, United States|Bond Community Health Center, Tallahassee, Florida, United States|Tallahassee Memorial, Tallahassee, Florida, United States|USF Tampa General Hospital, Tampa, Florida, United States|Alliance Clinical Research, Tampa, Florida, United States|Hawaii Pacific Health, Honolulu, Hawaii, United States|Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States|UIC - Mile Square, Chicago, Illinois, United States|Jesse Brown VA, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Olivo Wellness Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Ascension Via Christi, Wichita, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Jadestone Clinical Research, LLC, Gaithersburg, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|GFC of Southeastern Michigan, Detroit, Michigan, United States|SRI International, Plymouth, Michigan, United States|Metro Health-University of Michigan Health, Wyoming, Michigan, United States|Raritan Bay Primary Care and Cardiology Associates, Matawan, New Jersey, United States|G&S Medical Associates, LLC, Paterson, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Strong Memorial, Rochester, New York, United States|Spinal Pain and Rehab Medicine, Yonkers, New York, United States|Duke, Durham, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|The Heart and Medical Center, Durant, Oklahoma, United States|Ascension St. John Clinical Research Institute, Tulsa, Oklahoma, United States|UPMC Passavant Cranberry, Cranberry, Pennsylvania, United States|UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC East, Monroeville, Pennsylvania, United States|UPMC Magee, Pittsburgh, Pennsylvania, United States|UPMC Presby, Pittsburgh, Pennsylvania, United States|UPMC Mercy, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|UPMC Shadyside, Pittsburgh, Pennsylvania, United States|UPMC Passavant McCandless, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Pharma Tex Research, Amarillo, Texas, United States|Ascension Seton Medical Center, Austin, Texas, United States|Baptist Beaumont, Beaumont, Texas, United States|McGoven Medical School - UT- Houston, Houston, Texas, United States|Diversifield Medical Practices, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Mesquite Regional Internal Medicine, Mesquite, Texas, United States|University of Texas at Tyler, Tyler, Texas, United States|University of Texas at Rio Grande Valley, Weslaco, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|Community Care of Clay, Clay, West Virginia, United States|University Healthcare Physicians, Harpers Ferry, West Virginia, United States|Community Care of Weston, Weston, West Virginia, United States|Gundersen Health System, La Crosse, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04498273/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04498273/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT04498273"
18,"NCT04320615","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVACTA","Completed","Has Results","COVID-19 Pneumonia","Drug: Tocilizumab (TCZ)|Drug: Placebo","Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4)|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Hospital Discharge or ""Ready for Discharge""|Incidence of Mechanical Ventilation by Day 28|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4)|Duration of ICU Stay to Day 28 (Week 4)|Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 14|Time to Clinical Failure to Day 28 (Week 4)|Mortality Rate at Day 28 (Week 4)|Time to Recovery to Day 28 (Week 4)|Duration of Supplemental Oxygen to Day 28 (Week 4)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","452","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42380|2020-001154-22","April 3, 2020","June 24, 2020","July 28, 2020","March 25, 2020","June 30, 2021","June 30, 2021","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Köln; Innere Medizin I; Onkologie, Hämatologie, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St George's Clinical Research Facility, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT04320615/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT04320615/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04320615"
19,"NCT04372186","A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia","EMPACTA","Active, not recruiting","Has Results","COVID-19 Pneumonia","Drug: Placebo|Drug: Tocilizumab","Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or >/= 2 Liters (L) Supplemental Oxygen)|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (Whichever Occurred First)|Mortality Rate by Day 28|Clinical Status on 7-Category Ordinal Scale at Day 28|Percentage of Participants With Adverse Events","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","377","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ML42528","May 14, 2020","August 18, 2020","December 1, 2021","May 1, 2020","September 27, 2021","September 27, 2021","Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|El Centro Regional Medical Center, El Centro, California, United States|eStudySite, La Mesa, California, United States|Highland Hospital Oakland, Oakland, California, United States|St. Joseph'S Hospital, Orange, California, United States|San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|Miami Veterans Administration Healthcare System - NAVREF, Miami, Florida, United States|University of Miami Pulmonary, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St. Lukes Boise Medical Center, Boise, Idaho, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Holy Cross Germantown Hospital, Germantown, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|St. Barnabas Hospital, Bronx, New York, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Flushing Hospital, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Harlem Hospital, New York, New York, United States|Canton-Potsdam Hospital, Potsdam, New York, United States|Novant Health Presbyterian Medical Center (Presbyterian Hospital), Charlotte, North Carolina, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|McAllen Medical Center, McAllen, Texas, United States|Sentara Medical Group, Virginia Beach, Virginia, United States|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Centro Multidisciplinar de Estudos Clínicos CEMEC FMABC, Sao Bernardo Do Campo, SP, Brazil|BR Trials - Pesquisa Clínica, Sao Paulo, SP, Brazil|Aga Khan University Hospital, Nairobi, Kenya|Organismo Publico Descentralizado Hospital Juarez de Mexico, Ciudad De México, Mexico|Hospital General de Culiacan, Culiacan, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Hospital Militar Central, Jesus Maria, Peru|Hospital Nacional Sergio E. Bernales, Lima, Peru|Hospital Nacional Arzobispo Loayza; Oncology, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Hospital Nacional Hipolito; Unanue, Lima, Peru|Hospital Maria Auxiliadora, Lima, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|University of the Free State, Bloemfontein, South Africa|George Provincial Hospital, George, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Milpark Hospital, Parktown West, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT04372186/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT04372186/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04372186"
20,"NCT04409262","A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia","REMDACTA","Completed","Has Results","COVID-19 Pneumonia","Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo","Time to Hospital Discharge or ""Ready for Discharge"" up to Day 28|Time to Mechanical Ventilation or Death up to Day 28|Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 14|Time to Death up to Day 28|Time to Death up to Day 60|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-category Ordinal Scale of Clinical Status up to Day 28|Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 7|Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 21|Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 28|Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 60|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline (Participants Who Did Not Require Mechanical Ventilation at Baseline)|Proportion of Participants Who Are Alive and Free of Respiratory Failure at Day 28 and Day 60 (Participants Requiring Mechanical Ventilation at Baseline)|Duration of Mechanical Ventilation (Participants Requiring Mechanical Ventilation at Baseline) up to Day 28|Difference in Mortality at Days 14, 28, and 60|Time to Recovery up to Day 28|Proportion of Participants Who Are Discharged or ""Ready for Discharge"" up to Day 28|Proportion of Participants Who Require Initiation of Mechanical Ventilation Post-baseline or Die up to Day 28","Hoffmann-La Roche|Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","649","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42511|2020-002275-34","June 16, 2020","February 1, 2021","March 8, 2021","June 1, 2020","February 14, 2022","February 14, 2022","Valleywise Health Medical Center, Phoenix, Arizona, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Hoag Hospital Irvine, Irvine, California, United States|Providence St Johns Health Center, Santa Monica, California, United States|Yale University School of Medicine; HIV Clinical Trials Program, New Haven, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St Luke's Health System; Rheumatology Research, Boise, Idaho, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Medical Center, Novi, Michigan, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Wyckoff Heights Medical Center, Staten Island, New York, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Providence Saint Vincent's Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|The Liver Institute at Methodist Dallas, Arlington, Texas, United States|Baylor Scott and White Medical Center - College Station, College Station, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor Scott & White Medical Center - Irving, Irving, Texas, United States|Baylor Scott & White Hospital - Plano, Plano, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|The Providence Regional Medical Center Everett, Everett, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil|Instituto de Pesquisa Clinica Evandro Chagas - IPEC FIOCRUZ, Rio de Janeiro, RJ, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, Sao Bernardo Do Campo, SP, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Instituto de Infectologia Emilio Ribas, Sao Paulo, SP, Brazil|Instituto do Coração - HCFMUSP, Sao Paulo, SP, Brazil|Medsi Clinic, Moscow, Adygeja, Russian Federation|O.M. Filatov City Clinical Hospital #15; Department of Surgery, Moskva, Moskovskaja Oblast, Russian Federation|City Pokrovskaya Hospital, Sankt-peterburg, Sankt Petersburg, Russian Federation|City Clinical Hospital # 52, Moscow, Russian Federation|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Principe de Asturias; Medicina Interna - Servicio de Enfermedades Infecciosas, Alcala de Henares, Madrid, Spain|Hospital Universitario HM Torrelodones, Torrelodones, Madrid, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04409262/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04409262/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04409262"
21,"NCT04529499","Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients",,"Terminated","Has Results","Covid19","Drug: AVIGAN|Drug: Placebo Comparator","Primary Efficacy Endpoint: Time to Resolution of Hypoxia (Stage I)|Percentage of Patients Dying (All Cause (Stage I)","Dr. Reddy's Laboratories Limited","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 3","353","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CVD-04-CD-001","August 22, 2020","January 22, 2021","January 27, 2021","August 27, 2020","March 21, 2022","March 21, 2022","Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait|Mishref Field Hospital (Mishref), Kuwait City, Kuwait","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04529499/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04529499/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04529499"
22,"NCT04317040","CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)","SAC-COVID","Completed","Has Results","Coronavirus Disease 2019 (COVID-19)","Drug: CD24Fc|Drug: Placebo","Time to Improvement in Coronavirus Disease 2019 (COVID-19) Clinical Status|Number of Participants Who Experience an Adverse Event (AE)|Percentage of Participants Who Died or Had Respiratory Failure (RF)|Time to Disease Progression in Clinical Status of COVID-19|Number of Participants Who Died Due to Any Cause|Rate of Clinical Relapse|Conversion Rate of COVID-19 Clinical Status|Time to Hospital Discharge|Duration of MV|Duration of Pressors|Duration of ECMO|Duration of High Flow Oxygen Therapy|Length of Hospital Stay|Change From Baseline in Absolute Lymphocyte Count|Change From Baseline in D-Dimer Concentration","OncoImmune, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","234","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7110-007|20200674|CD24Fc-007-US|MK-7110-007","April 24, 2020","October 20, 2020","October 20, 2020","March 20, 2020","October 15, 2021","October 15, 2021","Baptist Health Research Institute, Jacksonville, Florida, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|Shady Grove Medical Center, Rockville, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Cooper University Hospital, Camden, New Jersey, United States|Atlantic Health System, Morristown, New Jersey, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Texas at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT04317040/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04317040"
23,"NCT04358081","Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",,"Completed","Has Results","Covid-19","Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo","Number of Participants Who Achieved Clinical Response by Day 15|Number of Participants Who Achieved Viral Clearance|Number of Participants Discharged or Ready for Discharge|Time to Return to Pre-morbid Supplemental Oxygen Requirement in Participants Receiving Hydrochloroquine or Hydrochloroquine Plus Azithromycin Relative to Placebo","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CJWT629A12301","May 1, 2020","July 27, 2020","July 27, 2020","April 22, 2020","March 17, 2021","October 11, 2021","Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04358081/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04358081/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04358081"
24,"NCT04355767","Convalescent Plasma in Outpatients With COVID-19","C3PO","Completed","Has Results","Covid19","Biological: Convalescent Plasma|Biological: Saline","Number of Patients With Disease Progression (Intention-to-treat Population)|Number of Patients With Disease Progression (Per-protocol Population)|Worst Severity Rating on the WHO COVID Ordinal Scale for Clinical Improvement During the 30 Days Following Randomization|Number of Patients With Worsening of Symptoms at Day 15 as a Measure of Time to Disease Progression|Number of Hospital-free Days During the 30 Days Following Randomization|All-cause Mortality","Stanford University|National Heart, Lung, and Blood Institute (NHLBI)|Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network|University of Pittsburgh|Medical University of South Carolina","All","18 Years and older   (Adult, Older Adult)","Phase 3","511","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","C3PO|1OT2HL156812-01","August 11, 2020","March 29, 2021","March 29, 2021","April 21, 2020","October 19, 2021","October 19, 2021","Chandler Regional Medical Center, Chandler, Arizona, United States|Valleywise Health Medical Center, Phoenix, Arizona, United States|UCSD Health La Jolla, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Stanford University, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Spectrum Health Hospitals Butterworth Hospital, Grand Rapids, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|HealthPartners Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|William P. Clements Jr. University Hospital, Dallas, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University of Utah Healthcare, Salt Lake City, Utah, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04355767/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04355767/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04355767"
25,"NCT04523831","Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection",,"Completed","Has Results","Covid19","Drug: Ivermectin and Doxycycline|Drug: Standard of care","Number of Patients With Early Clinical Improvement|Number of Participants With Late Clinical Recovery|Number of Patients Having Clinical Deterioration.|Number of Patients Remain Persistently Positive for RT-PCR of Covid-19","Dhaka Medical College","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ERC-DMC/ECC/2020/117","June 1, 2020","August 22, 2020","September 10, 2020","August 24, 2020","October 9, 2020","October 9, 2020","Dhaka Medical College, Dhaka, Bangladesh","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04523831/Prot_ICF_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04523831/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04523831"
26,"NCT04332107","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","ACTION","Terminated","Has Results","COVID-19|SARS-CoV-2","Drug: Azithromycin|Drug: Placebos","Number of Participants Who Were Symptom Free at Day 14|Viral Load|Mortality|Adverse Events|Positive SARS-CoV-2 Test - Nasal Swab|Positive SARS-CoV-2 Test - Saliva Swab|Positive SARS-CoV-2 Test - Rectal Swab|Genetic Macrolide Resistance Determinants|Secondary Outcomes Through Day 21|Number of Participants With Emergency Room Visits|Number of Household Members With COVID-19 (Confirmed or Symptomatic)|Number of Participants That Died|Number of Participants Reporting Hospitalization","Thomas M. Lietman|Bill and Melinda Gates Foundation|Pfizer|Stanford University|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 3","263","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-30504","May 22, 2020","March 16, 2021","March 30, 2021","April 2, 2020","September 9, 2021","October 7, 2021","University of California San Francisco, San Francisco, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04332107/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04332107/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04332107"
27,"NCT04673214","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment",,"Completed","Has Results","Covid19","Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Drug: Azithromycin / Ribaroxaban / Paracetamol","Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.|Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS","Gilberto Cruz Arteaga|Coordinación de Investigación en Salud, Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 3","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","R-2020-785-176","December 16, 2020","February 25, 2021","February 25, 2021","December 17, 2020","August 16, 2021","August 16, 2021","Alma Italia Guerrero Martinez, Mexico, Distrito Federal, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04673214/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04673214/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04673214"
28,"NCT04372017","Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection",,"Terminated","Has Results","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D","Cohort A: Percentage of COVID-19 Exposed Healthcare Workers Treated With Hydroxychloroquine With a Positive COVID-19 Test.|Cohort B: Percentage of COVID-19 Exposed High-risk Individuals Treated With Hydroxychloroquine With a Positive COVID-19 Test.","Sanford Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PEPCOH","May 14, 2020","June 4, 2021","June 4, 2021","May 1, 2020","December 10, 2021","December 10, 2021","Sanford Health, Sioux Falls, South Dakota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04372017/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04372017/ICF_003.pdf","https://ClinicalTrials.gov/show/NCT04372017"
29,"NCT04505722","A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants","ENSEMBLE","Active, not recruiting","Has Results","Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol","Biological: Ad26.COV2.S|Other: Placebo","Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19) With Seronegative Status (Main Study)|Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 With Seronegative Status (Main Study)|Number of Participants With Solicited Local Adverse Events (AEs) Up to 7 Days After Booster Vaccination (Open-label Booster Vaccination Phase)|Number of Participants With Solicited Systemic AEs Up to 7 Days After Booster Vaccination (Open-label Booster Vaccination Phase)|Number of Participants With Unsolicited AEs Up to 28 Days After Booster Vaccination (Open-label Booster Vaccination Phase)|Number of Participants With Serious Adverse Events (SAEs) From Booster Vaccination Until End of the Study (Open-label Booster Vaccination Phase)|Number of Participants With Adverse Events of Special Interest (AESI) From Booster Vaccination Until End of the Study (Open-label Booster Vaccination Phase)|Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19) With Seronegative Status (Open-label Booster Vaccination Phase)|Number of Participants With First Occurrence of Molecularly Confirmed Severe/Critical Coronavirus Disease (COVID-19) With Seronegative Status (Open-label Booster Vaccination Phase)|Number of Participants With First Occurrence of Molecularly Confirmed Severe/Critical COVID-19 With Seronegative Status (Main Study)|Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of Their Serostatus (Main Study)|Number of Participants With First Occurrence of COVID-19 Requiring Medical Intervention (Main Study)|SARS-CoV-2 Viral Load as Assessed by Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) in Participants With Molecularly Confirmed, Moderate to Severe/Critical COVID-19 (Main Study)|Number of Participants With First Occurrence of Molecularly Confirmed Mild COVID-19 (Main Study)|Number of Participants With First Occurrence of Molecularly Confirmed COVID-19 Defined by the US Food and Drug Administration (FDA) Harmonized Case Definition (Main Study)|Number of Participants With Burden of Disease (BOD) Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19 (Main Study)|Number of Participant With BOD Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19 (Main Study)|Number of Participants With SARS-CoV-2 Seroconversion Based on Antibodies to N Protein Using ELISA and/or SARS-CoV-2 Immunoglobulin Assay (Main Study)|Number of Participants With Asymptomatic Infection Detected by RT-PCR at the Time of the Month 6/Unblinding Visit (Main Study)|Number of Participants With First Occurrence of SARS-CoV-2 Infection (Serologically and/or Molecularly Confirmed) (Main Study)|Number of Participants With Serious Adverse Events (SAEs) (Main Study)|Number of Participants With Adverse Events of Special Interest (AESI) (Main Study)|Number of Participants With Medically-Attended Adverse Events (MAAEs) (Main Study)|Number of Participants With MAAEs Leading to Study Discontinuation (Main Study)|Number of Participants With Solicited Local Adverse Events (AEs) During 7 Days Following Vaccination (Main Study)|Number of Participants With Solicited Systemic AEs During 7 Days Following Vaccination (Main Study)|Number of Participants With Unsolicited AEs During 28 Days Post-vaccination (Main Study)|Binding Antibodies to SARS-CoV-2 S Protein Assessed by ELISA (Main Study)","Janssen Vaccines & Prevention B.V.","All","18 Years and older   (Adult, Older Adult)","Phase 3","44325","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CR108876|VAC31518COV3001","September 7, 2020","March 31, 2023","March 31, 2023","August 10, 2020","April 15, 2022","July 6, 2022","Synexus Clinical Research US, Inc, Birmingham, Alabama, United States|University of Alabama Birmingham, Birmingham, Alabama, United States|Alabama Vaccine Research Clinic at UAB, Birmingham, Alabama, United States|Optimal Research, Huntsville, Alabama, United States|Synexus Clinical Research US, Inc, Glendale, Arizona, United States|VA Medical Center, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Ark Clinical Research, Long Beach, California, United States|Anthony Mills Medical, Inc, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCSD Antiviral Research Center AVRC, San Diego, California, United States|Wr-McCr, Llc, San Diego, California, United States|VA Medical Center, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Denver, Colorado, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|North Florida South Georgia Veteran Health System, Gainesville, Florida, United States|Velocity Clinical Research, Hallandale Beach, Hallandale Beach, Florida, United States|Research Centers of America, LLC, Hollywood, Florida, United States|Suncoast Research Group, Miami, Florida, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Advent Health Orlando, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Pinellas Park, Florida, United States|James A Haley VA Hospital GNS, Tampa, Florida, United States|Synexus Clinical Research US, Inc, The Villages, Florida, United States|Emory University of Medicine, Atlanta, Georgia, United States|The Hope Clinic at Emory University, Decatur, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Jesse Brown VAMC Department of Surgery, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of IL Chicago, Chicago, Illinois, United States|The University Of Chicago Medicine, Chicago, Illinois, United States|Optimal Research, Peoria, Illinois, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Benchmark Research, Metairie, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Southeast Louisiana Veterans Health Care Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Optimal Research, Rockville, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Brigham and Women's Hospital, Inc., Boston, Massachusetts, United States|University of Michigan Neuorsurgery A. Alfred Taubman Health Care Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Cherry Street Services, Inc., Grand Rapids, Michigan, United States|Abbott Northwestern Hospital Clinic, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|MediSync Clinical Research, Petal, Mississippi, United States|The Center For Pharmaceutical Research, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Saint Michaels Medical Center, Newark, New Jersey, United States|Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, United States|Bronx Veterans Affairs Medical Center, Bronx, New York, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|New York Blood Center, New York, New York, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|Tryon Medical Group, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Durham VAMC, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc, Akron, Ohio, United States|CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|Velocity Clinical Research, Cincinnati, Ohio, United States|Rapid Medical Research, Cleveland, Ohio, United States|Synexus Clinical Research US, Inc, Columbus, Ohio, United States|Corvallis Clinic PC, Corvallis, Oregon, United States|Clinical Research Institute of Southern Oregon, P.C., Medford, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|VA Medical Center, Columbia, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|PMG Research of Charleston, LLC, Mount Pleasant, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|Optimal Research, LLC, Austin, Texas, United States|AIDS Arms Incorporated Trinity Health and Wellness Center, Dallas, Texas, United States|Synexus Clinical Research US, Inc, Dallas, Texas, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|North Texas Infectious Diseases Consultants, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Gordon Crofoot, MD, Houston, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States|CIPREC, Buenos Aires, Argentina|Helios Salud Sa, Buenos Aires, Argentina|CEMEDIC, Buenos Aires, Argentina|Centro Medico Viamonte SRL, Ciudad Autonoma Buenos Aires, Argentina|Clinical Trials Division-Stamboulian Servicios de Salud, Ciudad Autonoma Buenos Aires, Argentina|Clínica y Maternidad Suizo Argentina, Ciudad Autonoma de Buenos Aires, Argentina|Fundacion Huesped, Ciudad Autonoma De Buenos Aire, Argentina|CEMIC Saavedra, Ciudad de Buenos Aires, Argentina|Hospital J. M. Ramos Mejía, Ciudad de Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|DIM Clinica Privada, Ramos Mejia, Argentina|Faculdade de Medicina Barretos FACISB, Barretos, Brazil|Hospital Das Clinicas Da Universidade Federal De Minas Gerais, Belo Horizonte, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil|L2IP - Instituto de Pesquisas Clínicas, Brasília, Brazil|HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil|Fundação Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil|Hospital São José, Criciúma, Brazil|Oncovida - Centro de Onco-Hematologia de Mato Grosso, Cuiabá, Brazil|Hospital Nossa Senhora Das Gracas, Curitiba, Brazil|Centro de Estudos e Pesquisas em Moléstias Infecciosas, Natal, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirão Preto, Brazil|Hospital federal dos servidores do estado, Rio de Janeiro, Brazil|Instituto Brasil de Pesquisa Clinica, Rio de Janeiro, Brazil|Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ, Rio de Janeiro, Brazil|Hospital Geral De Nova Igaucu Brazil, Rio de Janeiro, Brazil|Fundação Bahiana De Infectologia, Salvador, Brazil|Universidade Municipal de Sao Caetano do Sul, Sao Caetano do Sul, Brazil|Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Brazil|Instituto de infectologia Emilio Ribas, Sao Paulo, Brazil|Centro de Referencia E Treinamento Dst/Aids, Sao Paulo, Brazil|CPQuali Pesquisa Clinica LTDA ME, São Paulo, Brazil|Hospital Sirio Libanes, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Brazil|CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos, São Paulo, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Brazil|Centro de Estudios Clínicos e Investigación Médica (CeCim), Santiago, Chile|Facultad de Medicina Universidad de Chile, Santiago, Chile|Hospital Padre Hurtado, Santiago, Chile|Centro de Investigacion del Maule, Talca, Chile|Hospital Dr Hernan Henriquez Aravena, Temuco, Chile|Centro de Estudios Clínicos V Región Ltda, Viña del Mar, Chile|Clinica de la Costa, Barranquilla, Colombia|Centro de Reumatologia y Ortopedia, Barranquilla, Colombia|Hospital Universidad del Norte, Barranquilla, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Bogota, Colombia|Medplus Medicina Prepagada S.A., Bogota, Colombia|Solano y Terront Servicios Médicos Ltda., Bogota, Colombia|Centro de Investigaciones Clinicas S.A.S., Cali, Colombia|Fundación Valle del Lili, Cali, Colombia|Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca, Floridablanca, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia|Programa de Estudio y Control de Enfermedades Tropicales, Medellin, Colombia|Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia|Hospital Pablo Tobon Uribe, Medellín, Colombia|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico|Instituto Nacional de Salud Publica, Cuernavaca, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico|Unidad de Atención Medica e Investigacion en Salud (UNAMIS), Merida, Mexico|Centro Medico Nacional Siglo XXI IMSS, Mexico, Mexico|CAIMED Investigacion en salud S.A de C.V., Mexico, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico|Hospital Universitario de Nuevo Leon 'Dr Jose Eleuterio Gonzalez', Monterrey, Mexico|Infectolab, Tijuana, Mexico|Centro de Invetigaciones Medicas, Callao, Peru|Centro de Investigaciones Tecnologicas, Biomedica y medio ambientales (CITBM), Callao, Peru|Asociacion Civil Selva Amazonica (ACSA), Iquitos, Peru|Asociacion Civil Impacta Salud y Educacion - Barranco, Lima - Barranco, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Asociacion Civil Via Libre, Lima, Peru|Instituto de Investigacion Nutricional, Lima, Peru|Asociacion Civil Impacta Salud y Educacion- San Miguel CRS, Lima, Peru|Josha Research, Bloemfontein, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|Family Clinical Research Unit FAM-CRU, Cape Town, South Africa|TASK Central, Cape Town, South Africa|Desmond Tutu HIV Foundation, Cape Town, South Africa|University of Cape Town IDM/CIDRI Research Site, Cape Town, South Africa|Desmond Tutu Hiv Foundation - University of Cape Town, Cape Town, South Africa|Masiphumelele Research Centre, Cape Town, South Africa|Ndlovu Elandsdoorn Site, Dennilton, South Africa|SA Medical Research Council, Durban, South Africa|SA Medical Research Council, Durban, South Africa|CRISMO Bertha Gxowa Research Centre, Johannesburg, South Africa|Shandukani Research Centre, Johannesburg, South Africa|The Aurum Institute Klerksdorp Clinical Research Centre, Klerksdorp, South Africa|Qhakaza Mbokodo Research Centre, KwaZulu-Natal, South Africa|South African Medical Research Council Chatsworth Clinical Research Site, KwaZulu-Natal, South Africa|Centre for the AIDS Programme of Research in South Africa, KwaZulu-Natal, South Africa|Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Nelson Mandela Academic Clinical Research Unit 'NeMACRU', Mthatha, South Africa|PHOENIX PHARMA (Pty) Ltd, Port Elizabeth, South Africa|MeCRU Clinical Research Unit, Pretoria, South Africa|Synexus Watermeyer, Pretoria, South Africa|The Aurum Institute Rustenburg Clinical Research Site, Rustenburg, South Africa|Setshaba Research Centre, Soshanguve, South Africa|Perinatal HIV Research Unit (PHRU), Kliptown, Soweto, South Africa|Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa|The Aurum Institute: Tembisa - Clinic 4, Tembisa, South Africa|CAPRISA Vulindlela Clinic, Vulindlela, South Africa|University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre, Westdene Johannesburg Gauteng, South Africa|SATVI, Brewelskloof Hospital, Worcester, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04505722/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04505722/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04505722"
30,"NCT04497987","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","BLAZE-2","Completed","Has Results","COVID-19|SARS-CoV2","Drug: Bamlanivimab|Drug: Placebo|Drug: Etesevimab","Percentage of Participants With COVID-19|Percentage of Participants With Moderate or Worse Severity COVID-19|Percentage of Participants With SARS-CoV-2|Percentage of Participants Who Are Hospitalized or Have Died Due to COVID-19|Percentage of Participants Who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Percentage of Participants Who Die Due to COVID-19|Pharmacokinetics (PK): Mean Concentration of Bamlanivimab Administered Alone","Eli Lilly and Company|National Institute of Allergy and Infectious Diseases (NIAID)|AbCellera Biologics Inc.|Shanghai Junshi Bioscience Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1180","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","18063|J2X-MC-PYAD|CoVPN #3501","August 2, 2020","January 16, 2021","May 20, 2021","August 4, 2020","February 4, 2022","February 4, 2022","Unv of AL Sch of Med Div of Infectious Diseases, Birmingham, Alabama, United States|Care Access Research, Phoenix, Arizona, United States|Allergy and Asthma Clin of NW Ark, Bentonville, Arkansas, United States|Care Access Research LLC, Huntington Beach, California, United States|Alta Bates SMC, Oakland, California, United States|University of Colorado-Anschultz Medical Campus, Aurora, Colorado, United States|NIAID, Miami, Florida, United States|NIAID, Decatur, Georgia, United States|Belmont Village Lincoln Park, Lincoln Park, Illinois, United States|Family Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Care Access Rch Lake Charles, Lake Charles, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|NIAID - National Institute of Allergy & Infectious Diseases, Bethesda, Maryland, United States|Care Access, Boston, Massachusetts, United States|St. Paul IDA-CARe, Saint Paul, Minnesota, United States|Care Access, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Hospital & Medical Center, Omaha, Nebraska, United States|Care Access Research - Bronx, Bronx, New York, United States|NIAD, Chapel Hill, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Univ of Cin College of Med, Cincinnati, Ohio, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Donahoe Manor, Bedford, Pennsylvania, United States|Belmont Village, West Univ, Houston, Texas, United States|Burke Internal Medicine and Research, Burke, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT04497987/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT04497987/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04497987"
31,"NCT04362137","Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm","RUXCOVID","Completed","Has Results","Cytokine Storm (Covid-19)","Drug: Ruxolitinib|Drug: Placebo","Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care|Clinical Status|Percentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status|Percentage of Patients With at Least One-point Improvement From Baseline in Clinical Status|Percentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status|Time to Improvement in Clinical Status|Mean Change From Baseline in the Clinical Status|Mortality Rate|Proportion of Patients Requiring Mechanical Ventilation|Duration of Hospitalization|Time to Hospital Discharge or to a NEWS2 Score of ≤2|Change From Baseline in NEWS2 Score|Change From Baseline in SpO2/FiO2 Ratio|Proportion of Patients With no Oxygen Therapy","Novartis Pharmaceuticals|Incyte Corporation|Novartis","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","432","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CINC424J12301|INCB 18424-368|2020-001662-11","May 2, 2020","October 17, 2020","October 17, 2020","April 24, 2020","June 2, 2021","October 11, 2021","Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, C A B A, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Blumenau, Santa Catarina, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sorocaba, SP, Brazil|Novartis Investigative Site, Rionegro, Antioquia, Colombia|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Colombes Cedex, France|Novartis Investigative Site, Eaubonne, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Estado de Mexico, Mexico|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Yenisehir/Izmir, Turkey|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT04362137/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT04362137/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04362137"
32,"NCT04362813","Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","CAN-COVID","Completed","Has Results","Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia","Drug: Canakinumab|Drug: Placebo","Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis|COVID-19-related Death After Study Treatment|Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP)|Geometric Mean Ratio to Baseline in the D-dimer|Geometric Mean Ratio to Baseline in Ferritin|Number of Participants With Treatment Emergent Adverse Events","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","454","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CACZ885D2310|2020-001370-30","April 30, 2020","September 16, 2020","December 22, 2020","April 27, 2020","August 16, 2021","January 24, 2022","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04362813/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04362813/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04362813"
33,"NCT04491994","Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression","COVID-19","Completed","Has Results","Covid19|Progression","Drug: HCQ","Number of Participants With Progression|Viral Clearance","UNICEF|Pak Emirates Military Hospital Rawalpindi, Pakistan","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","540","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sultan Mehmood Kamran 2","April 10, 2020","May 31, 2020","May 31, 2020","July 30, 2020","August 21, 2020","August 21, 2020","Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04491994/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04491994"
34,"NCT04728802","Proxalutamide Treatment for Hospitalized COVID-19 Patients",,"Completed","Has Results","Covid19|SARS (Severe Acute Respiratory Syndrome)","Drug: Proxalutamide|Drug: Placebo","14 Day Recovery Rate|28 Day Recovery Rate|28 Day Mortality Rate|Post-Randomization Time to Recover (Alive Hospital Discharge)","Applied Biology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","645","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","KP-DRUG-SARS-003","February 1, 2021","April 15, 2021","April 15, 2021","January 28, 2021","June 23, 2021","June 24, 2021","Hospital Regional José Mendes, Itacoatiara, Amazonas, Brazil|Hospital de Campanha de Manacapuru, Manacapuru, Amazonas, Brazil|Hospital Oscar Nicolau, Manaus, Amazonas, Brazil|Hospital Prontocord, Manaus, Amazonas, Brazil|Hospital Samel, Manaus, Amazonas, Brazil|Hospital Regional Dr. Hamilton Maia Cidae, Manicore, Amazonas, Brazil|Hospital Raimunda Francisca Dinelli da Silva, Maues, Amazonas, Brazil|Hospital Regional Jofre Cohen, Parintins, Amazonas, Brazil","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT04728802/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04728802"
35,"NCT04341441","Will Hydroxychloroquine Impede or Prevent COVID-19","WHIP COVID-19","Terminated","Has Results","COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2","Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment","To Determine if the Use of Hydroxychloroquine as Preventive Therapy Decreases the Rate of Acquisition of SARS-CoV 2 Infections With Clinical COVID-19 Disease in Study Participants for Each Randomized Treatment Arm as Compared to Placebo.|Determine the Effect of Hydroxychloroquine Dose in the Prevention of COVID-19 Viremia and Disease.|Assess the Impact of Chronic Weight-based Dosing of HCQ for COVID-19 Prevention.|Comparison of the Rate of SARS-CoV 2 Infections as Measured by IgM/IgG Seroconversion in Study Participants Receiving Randomized HCQ Versus Placebo.|Compare the Seroprevalence of SARS-CoV 2 IgM and/or IgG Positive Samples at Study Entry and Study Conclusion in All Participants Receiving HCQ Compared to Those Receiving Placebo.|Comparison of the Emergence of Clinical Symptoms or COVID-19 Diagnosis in Participants Presenting Asymptomatically at Study Entry But Identified as Seropositive by Serology at Entry Between the Randomized Treatment Arms and Comparator Arm.|To Examine the Level of Care Needed by Participants in Each Arm Developing COVID19 as Measured as Requiring Emergency Room Visit, Hospitalization or Able to Stay Home Without Hospital Care.|Determine the Safety and Tolerability of HCQ Dosing for Preventive Strategy Against COVID-19 as Measured by Adverse Events and Serious Adverse Events.|To Examine Other Clinical Factors Contributing to the Risk of SARS-CoV 2 Infection in Healthcare Workers and First Responders.|Examine the Correlation Between HCQ Drug Levels and Development of COVID-19 Symptoms or Positive COVID-19 Test Results.|Identify Immunologic, Serological and Inflammatory Markers Associated With Acquisition and Response to COVID-19 in Both HCQ and Placebo Participants Developing Laboratory or Clinical Confirmed Disease.","Henry Ford Health System","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","624","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","1410401","April 7, 2020","December 15, 2020","December 15, 2020","April 10, 2020","June 21, 2022","June 21, 2022","Henry Ford Hospital, Detroit, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT04341441"
36,"NCT04546581","Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)",,"Completed","Has Results","COVID|COVID-19|SARS-CoV-2|SARS (Severe Acute Respiratory Syndrome)","Biological: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Other: Placebo|Drug: Remdesivir","Ordinal Outcome Scale - Day 7|Primary Safety Outcome - Death, SAE or Grade 3 or 4 Events Through Day 7|N Reaching 3 Least Favorable Categories|N Reaching 2 Most Favorable Categories|N Discharged or in Most Favorable Category","University of Minnesota|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)|International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)","All","18 Years and older   (Adult, Older Adult)","Phase 3","593","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INSIGHT 013","October 8, 2020","May 21, 2021","May 21, 2021","September 14, 2020","April 4, 2022","April 4, 2022","Penrose Hospital, Colorado Springs, Colorado, United States|St. Francis Health Services, Colorado Springs, Colorado, United States|St. Anthony Hospital, Lakewood, Colorado, United States|Saint Anthony North Health Campus, Westminster, Colorado, United States|Washington VA Medical Center, Washington, District of Columbia, United States|Redmond Regional Medical Center, Rome, Georgia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Hennepin Healthcare Research Institute/HCMC, Minneapolis, Minnesota, United States|University of Missouri, Columbia, Missouri, United States|Cox Medical Centers, Springfield, Missouri, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|Ohio Health Research Institute, Columbus, Ohio, United States|Hendrick Medical Center, Abilene, Texas, United States|CHRISTUS Spohn Shoreline Hospital, Corpus Christi, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|CJW Chippenham Medical Center, Richmond, Virginia, United States|Henrico Doctors' Hospital (HCA), Richmond, Virginia, United States|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|CHIP, Department of Infectious Diseases, Section 2100, Copenhagen, Denmark|Herlev-Gentofte Hospital, Hellerup, Denmark|Nordsjællands Hospital, Hillerød, Hillerød, Denmark|Hvidovre University Hospital, Department of Infectious Diseases, Hvidovre, Denmark|Kolding Sygehus, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Democritus University of Thrace, Alexandroupoli, Thrace, Greece|3rd Dept of Medicine, Medical School, NKUA, Athens, Greece|1st Respiratory Medicine Dept, Athens University Medical School, Athens, Greece|Attikon University General Hospital, Athens, Greece|Dept. of Critical Care & Pulmonary Medicine, Evangelismos General Hospital, Athens, Greece|NCGM, Tokyo, Japan|Fujita Health University Hospital, Toyoake, Japan|Institute of Human Virology-Nigeria (IHVN), Abuja, Nigeria|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Royal Free Hospital, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04546581/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04546581/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04546581/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04546581"
37,"NCT04860258","COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities",,"Terminated","Has Results","Coronavirus|Covid19|SARS-CoV-2|Severe Acute Respiratory Syndrome","Biological: CVnCoV Vaccine","Number of Participants Who Experienced a Solicited Adverse Event (AE) Occurring on the Day of Vaccination and the Following 7 Days After Any Dose|Intensity of Solicited AEs Per US Food and Drug Administration (FDA) Toxicity Grading Scale Occurring on the Day of Vaccination and the Following 7 Days After Any Dose|Duration of Solicited AEs Occurring on the Day of Vaccination and the Following 7 Days After Any Dose|Number of Participants Who Experienced an Unsolicited AE Occurring on the Day of Vaccination and the Following 28 Days After Any Dose|Intensity of Unsolicited AEs Per the Investigator's Assessment Occurring on the Day of Vaccination and the Following 28 Days After Any Dose|Number of Participants Who Experienced a Serious Adverse Event (SAE) During the Trial|Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) During the Trial|Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Receptor-Binding Domain (RBD) Antibodies on Day 43|Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein RBD Antibodies on Day 43|Subset Participants: Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies on Day 43|Subset Participants: GMTs of Serum SARS-CoV-2 Neutralizing Antibodies on Day 43|Number of Participants Seroconverting for SARS-CoV-2 Spike Protein RBD Antibodies on Days 29, 120, 211 and 393|GMTs of Serum SARS-CoV-2 Spike Protein RBD Antibodies on Days 29, 120, 211 and 393|Subset Participants: Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies on Days 29 and 120|Subset Participants: GMTs of Serum SARS-CoV-2 Neutralizing Antibodies on Days 29 and 120","CureVac AG","All","18 Years and older   (Adult, Older Adult)","Phase 3","129","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CV-NCOV-003|2020-004070-22","April 22, 2021","September 21, 2021","September 21, 2021","April 26, 2021","May 13, 2022","May 13, 2022","Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium|Université Libre de Bruxelles (ULB) - Hopital Erasme, Brussels, Belgium|Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Brussels, Belgium|Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman, Liège, Belgium","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04860258/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04860258/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04860258"
38,"NCT04315298","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19",,"Completed","Has Results","COVID-19","Drug: Sarilumab|Drug: Placebo","Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)|Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)|Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)|Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)|Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)|Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)|Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)|Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)|Time to Improvement in Oxygenation for at Least 48 Hours (Phase 2)|Time to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)|Time to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)|Percentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)|Time to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)|Change From Baseline in NEWS2 Scoring System (Phase 2)|Number of Days With Fever (Phase 2)|Percentage of Participants Alive, Off Oxygen (Phase 2)|Number of Days of Resting Respiratory Rate >24 Breaths/Min (Phase 2)|Number of Days With Hypoxemia (Phase 2)|Number of Days of Supplemental Oxygen Use (Phase 2)|Time to Saturation ≥94% on Room Air (Phase 2)|Number of Ventilator Free Days (Phase 2)|Number of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)|Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)|Number of Days of Hospitalization Among Survivors (Phase 2)|Number of Deaths Due to Any Cause|Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)|Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)|Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)|Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)|Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)|Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)|Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)|Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Time to Recovery (Phase 3 Cohort 1: Critical ITT)|Time to Recovery (Phase 3 Cohort 2)|Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Time to Death (Phase 3 Cohort 1: Critical ITT)|Time to Death (Phase 3 Cohort 2)|Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)|Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)|Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)|Number of Participants With Any Serious Adverse Event|Number of Participants With Grade 4 Neutropenia (ANC <500/mm3)|Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection|Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection|Number of Participants With Grade >=2 Infusion Related Reactions|Number of Participants With Grade >=2 Hypersensitivity Reactions|Number of Participants With Gastrointestinal Perforation|Mean Observed Leukocyte Values Across Study Days (Phase 2)|Mean Observed Leukocyte Values Across Study Days (Phase 3)|Mean Observed Hemoglobin Values Across Study Days (Phase 2)|Mean Observed Hemoglobin Values Across Study Days (Phase 3)|Mean Observed Platelet Count Across Study Days (Phase 2)|Mean Observed Platelet Count Across Study Days (Phase 3)|Mean Observed Total Bilirubin Values Across Study Days (Phase 2)|Mean Observed Total Bilirubin Across Study Days (Phase 3)|Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)|Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)|Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)|Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)|Mean Observed Creatinine Values Across Study Days (Phase 2)|Mean Observed Creatinine Values Across Study Days (Phase 3)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1912","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-COV-2040","March 18, 2020","July 24, 2020","September 2, 2020","March 19, 2020","September 23, 2021","September 23, 2021","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04315298"
39,"NCT04427501","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness","BLAZE-1","Completed","Has Results","COVID-19","Drug: LY3819253|Drug: LY3832479|Drug: Placebo","Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause in 2800 mg Bamlanivumab/2800 mg Etesevimab, 700 mg Bamlanivimab/1400mg Etesevimab and Their Placebo Groups|Phase 3: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than a Prespecified Threshold in Arms 350 mg Bamlanivimab/700 mg Etesevimab and Placebo|Phase 2: Change From Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load|Phase 2: Percentage of Participants Who Experience a Serious Adverse Event(s) SAE(s)|Phase 3: Percentage of Participants Demonstrating Symptom Resolution|Phase 3: Percentage of Participants Demonstrating Symptom Improvement|Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death From Any Cause|Phase 3: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load|Phase 3: Time to Sustained Symptom Resolution|Phase 3: Time to SARS-CoV-2 Viral Clearance|Phase 2: Change From Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled With Recent Symptoms Prior to Randomization|Phase 2: Percentage of Participants Demonstrating Symptom Resolution|Phase 2: Percentage of Participants Demonstrating Symptom Improvement|Phase 2, Pharmacokinetics (PK): Mean Concentration of Bamlanivimab Alone and in the Presence of Etesevimab|Phase 2, PK: Mean Concentration of Etesevimab in the Presence of Bamlanivimab|Phase 2: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death From Any Cause|Phase 2: Time to SARS-CoV-2 Viral Clearance","Eli Lilly and Company|AbCellera Biologics Inc.|Shanghai Junshi Bioscience Co., Ltd.","All","Child, Adult, Older Adult","Phase 2|Phase 3","3290","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17947|J2W-MC-PYAB","June 17, 2020","February 16, 2021","December 14, 2021","June 11, 2020","March 7, 2022","March 7, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Clin Trials-Mesa, Mesa, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Sun City West, Arizona, United States|Fiel Family and Sports Medicine PC, Tempe, Arizona, United States|Orange Grove Banner Clinic, Tucson, Arizona, United States|Arizona Clin Trials-Tucson, Tucson, Arizona, United States|Arkansas Children's, Little Rock, Arkansas, United States|KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States|Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States|Smart Cures Clin Research, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|VCT-Covina, Covina, California, United States|AMCR Institute, Escondido, California, United States|Chemidox Clinical Trials, Lancaster, California, United States|Ark Clinical Research, Long Beach, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Mattel Children's Hospital, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Zion Medical Center, San Diego, California, United States|Kaiser Permanente - SD Med Ctr, San Diego, California, United States|Wolverine Clinical Trials, LLC, Santa Ana, California, United States|St. Joe Heritage HC-Santa Rosa, Santa Rosa, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|South Bay Clinical Research Institute, Torrance, California, United States|Infect Disease Doctors Med Grp, Walnut Creek, California, United States|Allianz Research Institute, Westminster, California, United States|Future Innovative Treatments LLC, Colorado Springs, Colorado, United States|Nemours Childrens Clinic - Delaware Valley of The Nemours Foundation, Wilmington, Delaware, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Synergy Healthcare LLC, Bradenton, Florida, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Elixia CRC, Hollywood, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|Lakeland Regional Medical Center, Lakeland, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Hope Clinical Trials, Inc., Miami, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Bio-Medical Research, LLC, Miami, Florida, United States|Clinical Site Partners, LLC d/b/a CSP Miami, Miami, Florida, United States|GCPR, Saint Petersburg, Florida, United States|Testing Matters Lab, Sunrise, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|Triple O Research Inst, West Palm Beach, Florida, United States|Encore Medical Research - Weston, Weston, Florida, United States|Clinical Site Partners, LLC DBA CSP Orlando, Winter Park, Florida, United States|Gwinnett Research Inst, Buford, Georgia, United States|Paramount Rch Sol - College Pk, College Park, Georgia, United States|IACT Health - VHC, Columbus, Georgia, United States|Central Georgia Infectious Disease, Macon, Georgia, United States|Rophe Adult and Pediatric Medicine, Union City, Georgia, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|J H. Stroger Hosp of Cook Co, Chicago, Illinois, United States|University of Chi Med Center, Chicago, Illinois, United States|Great Lakes Clinical Trials - Andersonville, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Qualmedica Research Evansville, Evansville, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|St.Vincent - Indy, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Qualmedica Research, LLC, Owensboro, Kentucky, United States|Tandem Clinical Research,LLC, Marrero, Louisiana, United States|Imperial Health Urgent Care Center - Moss Bluff, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Institute for Advanced Clinical Trials for Children, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|University of Michigan Health Systems, Ann Arbor, Michigan, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Childrens Hospital of Michigan, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Revive Research Institute, Farmington Hills, Michigan, United States|Revival Research Institute, Sterling Heights, Michigan, United States|Sky Clinical Prime and Health Wellness Clinic, Fayette, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Sky Clin Resch - Quinn HC, Ridgeland, Mississippi, United States|Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States|Be Well Clinical Studies, Lincoln, Nebraska, United States|Childrens Endocrine Clinic, Omaha, Nebraska, United States|Quality Clinical Research, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|SG Clinical Research - PC, Las Vegas, Nevada, United States|Robert Wood Johnson University Medical School, New Brunswick, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Care Access Research - Bronx, Bronx, New York, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|OnSite Clinical Solutions, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Monroe Biomed Research, Monroe, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Carolina Research Center, Inc., Shelby, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Hometown UC and Rch- Cincy, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|OH State Univ College of Med, Columbus, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Dayton, Ohio, United States|META Medical Research Institute, Dayton, Ohio, United States|Ascension St. John Tulsa OK, Tulsa, Oklahoma, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Hasbro Children's Hospital, Providence, Rhode Island, United States|VITALINK - Anderson, Anderson, South Carolina, United States|Carolina Medical Research - Clinton, Clinton, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|Carolina Medical Research - Greenville, Greenville, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Univ Diab & Endo Consult, Chattanooga, Tennessee, United States|New Phase Research and Development, Knoxville, Tennessee, United States|St Jude Childrens Research Hospital, Memphis, Tennessee, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Conroe Willis Medical Research, Conroe, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|North Texas Clinical Trials, LLC, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Centex-Houston, Houston, Texas, United States|Accurate Clinical Management, LLC., Houston, Texas, United States|BioPharma Clinc Site, Houston, Texas, United States|Centex-Wesfield, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|Zion Urgent Care Clinic, Katy, Texas, United States|BioPharma Family Practice Center McAllen, McAllen, Texas, United States|BRCR Medical Center, Inc, McAllen, Texas, United States|North Hills Medical Research, North Richland Hills, Texas, United States|Bay Area Infectious Diseases Associates, Pasadena, Texas, United States|Epic Medical Research, Red Oak, Texas, United States|Baylor - Round Rock, Round Rock, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|APD Clinical Research, Splendora, Texas, United States|Baylor Scott and White Medical Center, Temple, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CLS Research Ctr, PLLC, Webster, Texas, United States|CARE ID, Annandale, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Dorado Medical Complex Inc, Dorado, Puerto Rico|GCM Medical Group, PSC - Hato Rey Site, San Juan, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04427501/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04427501/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04427501"
40,"NCT04460183","A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19",,"Completed","Has Results","COVID-19","Drug: RESP301, a Nitric Oxide generating solution|Other: Standard of Care","Number of Participants Who Progress by at Least One Level Higher on the Modified WHO Ordinal Scale|Change in Room Air Oxygen Saturation (SpO2) From Baseline Over Time|Change in National Early Warning Score (NEWS) 2 Symptom Score From Baseline Over Time|Change From Baseline for Number of Participants on the Modified WHO Ordinal Scale at Each Visit|Time to Improvement of at Least One Level Lower on the Modified WHO Ordinal Scale|Time to Progression of at Least One Level Higher on the Modified WHO Ordinal Scale|Number of Participants With Adverse Events|Time to Hospital Discharge|Number of Participants With Mortality by Day 28|Reduction in Oxygen Saturation (SpO2) to <90%|Events of Clinical Bronchial Hyper Responsiveness Related to Nebulization","Thirty Respiratory Limited","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RESP301-002","July 29, 2020","April 24, 2021","May 21, 2021","July 7, 2020","June 2, 2022","June 2, 2022","Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, United Kingdom|Royal Preston Hospital, Preston, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT04460183/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT04460183/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04460183"
41,"NCT04380519","Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)",,"Completed","Has Results","COVID-19","Drug: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo","Proportion of Responders in Each Treatment Group|Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale|The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab|The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study|Mortality Rate During the Study","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","372","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CL04041078","April 23, 2020","July 10, 2020","July 24, 2020","May 8, 2020","January 24, 2022","January 24, 2022","Private healthcare institution ""Clinical Hospital"" Russian Railways-Medicine named after N. A. Semashko"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Autonomous Education Institution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of the Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budgetary Institution ""Central Clinical Hospital with Polyclinic"" of Administrative Directorate of the President of the Russian Federation, Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|State budgetary healthcare institution City Clinical Hospital named after S.I. Spasokukotsky Department of Health of the city of Moscow City Clinical Hospital No. 50, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Volga Research Medical University"" of the Ministry of Health of the Russian Federation, Nizhniy Novgorod, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation|Federal Budgetary State Healthcare Institution ""National Medical Research Center named after B.A. Almazov"", Saint-Petersburg, Russian Federation|Budgetary Health Institution Voronezh Regional Clinical Hospital №1, Voronezh, Russian Federation|State Budget Healthcare Institution of Yaroslavl Region ""Yaroslavl Region Clinical Hospital of War Veterans"", Yaroslavl, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04380519/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04380519"
42,"NCT04401293","Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients",,"Completed","Has Results","Sars-CoV2|COVID","Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin","Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days.|Major Bleeding|Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Hospital Day 10 + 4|Sepsis-induced Coagulopathy (SIC) Score|Progression to Acute Respiratory Distress Syndrome (ARDS)|Need for Intubation|Re-hospitalization","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","257","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-0340","April 26, 2020","May 14, 2021","May 14, 2021","May 26, 2020","November 22, 2021","November 22, 2021","Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04401293/Prot_SAP_003.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04401293/ICF_004.pdf","https://ClinicalTrials.gov/show/NCT04401293"
43,"NCT04502472","Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma","Inova-CCP","Terminated","Has Results","Covid-19","Biological: Convalescent plasma transfusion","Change is Clinical Status|Transfusion Related Events Due to Administration of CCP|Length of Hospital Stay|Mechanical Ventilation|Change in Mechanical Ventilation Status|Mortality","Inova Health Care Services","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","109","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Inova COVID-19 CCP","June 6, 2020","September 30, 2020","September 30, 2020","August 6, 2020","January 10, 2022","January 10, 2022","Inova Fairfax Medical Campus, Falls Church, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT04502472/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT04502472"
44,"NCT04369469","Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia",,"Terminated","Has Results","COVID-19 Severe Pneumonia|Acute Lung Injury|Acute Respiratory Distress Syndrome|Pneumonia, Viral","Biological: Ravulizumab|Other: BSC","Survival (Based On All-Cause Mortality) in Participants in the ITT Population At Day 29|Number Of Days Free Of Mechanical Ventilation At Day 29|Number of Days the Participants Were Alive and Not in ICU|Change From Baseline In Sequential Organ Failure Assessment (SOFA) At Day 29|Change From Baseline In Peripheral Capillary Oxygen Saturation/Fraction Of Inspired Oxygen (SpO2/FiO2) At Day 29|Number of Days the Participants Were Alive and Not in the Hospital|Estimated Number of Participants Alive At Up To Day 60 and At Up To Day 90|Serum Ravulizumab Concentrations Prior to Dosing on Day 1 and Day 29|Change From Baseline In Serum Free Complement Component 5 Concentrations At Day 29|Change From Baseline In Terminal Complement Complex C5b-9 At Day 29","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-COV-305","May 10, 2020","February 8, 2021","April 8, 2021","April 30, 2020","May 24, 2022","May 24, 2022","Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|LAC/USC Health Center, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Norton Healthcare, Louisville, Kentucky, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Health Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|Mayo Clinic Health System in Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System, La Crosse, Wisconsin, United States|Hôpital Raymond Poincaré, Garches, Hauts De Seine, France|Hôpital Henri Mondor, Créteil, Val De Marne, France|Hôpital Bicêtre, Le Kremlin-Bicêtre cedex, Val De Marne, France|Medical Hospital, Tokyo Medical and Dental University, Bunkyō-Ku, Tokyo-To, Japan|Jikei University Hospital, Minato-Ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku-Ku, Tokyo, Japan|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|King's College Hospital, London, Greater London, United Kingdom|Hammersmith Hospital, London, Greater London, United Kingdom|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT04369469/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT04369469/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04369469"
45,"NCT04435795","Inhaled Ciclesonide for Outpatients With COVID19","CONTAIN","Terminated","Has Results","COVID 19","Drug: Normal Saline intranasal and placebo inhaler|Drug: Ciclesonide|Drug: Ciclesonide nasal","Proportion of Participants With no Symptoms of Cough, Fever or Dyspnea|Overall Feeling: Proportion Who Are Reporting That They Are ""Very Much Improved"" or ""Much Improved"" at Day 7|Overall Feeling: Proportion Who Are Reporting That They Are ""Very Much Improved"" or ""Much Improved"" at Day 14|Improvement in Dyspnea: Resolution of Dyspnea at Day 7|Improvement in Cough at Day 7: Proportion of Patient With a Reduction of Cough Symptoms at Day 7|Proportion of Participants Hospitalized for SARS-CoV-2|Mortality","McGill University Health Centre/Research Institute of the McGill University Health Centre","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","215","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2021-6696","September 15, 2020","June 8, 2021","July 8, 2021","June 17, 2020","April 29, 2022","June 10, 2022","University of British Columbia, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT04435795/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04435795"
46,"NCT04332991","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","ORCHID","Completed","Has Results","Coronavirus|Acute Respiratory Infection|SARS-CoV Infection","Drug: Hydroxychloroquine|Drug: Placebo","COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization)|All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)|All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)|Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28|Oxygen-free Days Through Day 28|Ventilator-free Days Through Day 28|Vasopressor-free Days Through Day 28|ICU-free Days to Day 28|Hospital-free Days to Day 28","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","479","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PETAL 05 Orchid","April 2, 2020","June 19, 2020","July 23, 2020","April 3, 2020","March 17, 2021","March 17, 2021","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04332991/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04332991/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04332991"
47,"NCT04353271","Trial of Hydroxychloroquine In Covid-19 Kinetics","THICK","Terminated","Has Results","Covid 19|Corona Virus Infection","Drug: Hydroxychloroquine|Other: Placebo","Number of Participants Who Are Virus Free|Disease Severity|Number of Participants Who Are Hospitalized for Covid 19 Infection|Number of Participants Who Die Secondary to Covid 19 Infection|Number of Participants Who Have Confirmed Covid 19 Infection|Number of Participants Who Discontinue or Withdraw Medication Use for Any Reason|Immunity to Covid-19","University of South Alabama","All","19 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","[1582736-1]","April 17, 2020","July 8, 2020","July 8, 2020","April 20, 2020","January 3, 2022","January 3, 2022","University of South Alabama, Mobile, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04353271/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04353271"
48,"NCT04334148","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","HERO-HCQ","Completed","Has Results","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of Participants With Clinical Infection With COVID-19 Infection|Number of Participants With COVID-19 Viral Shedding|Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs)","Adrian Hernandez|Patient-Centered Outcomes Research Institute|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 3","1360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Pro00105274","April 22, 2020","December 10, 2020","January 9, 2021","April 6, 2020","October 7, 2021","October 12, 2021","Children's Hospital Colorado/University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|University of Florida Health Central Florida, Leesburg, Florida, United States|University of Miami Florida, Miami, Florida, United States|Advent Health, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Northwestern Medicine, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States|University of Missouri-Columbia, Columbia, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hospital for Special Surgery, New York, New York, United States|Columbia University, Irving Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White Medical Center-Temple, Temple, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic Health System, Marshfield, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04334148/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04334148/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04334148"
49,"NCT04794803","Reparixin in COVID-19 Pneumonia - Efficacy and Safety",,"Terminated","Has Results","Severe Pneumonia","Drug: Reparixin|Drug: Standard of care","Phase 2 - Percentage of Participants With Composite Endpoint of Clinical Events|Phase 2 - Percentage of Patients With Improvement in Clinical Severity Score (as Recommended by WHO for COVID Studies) of at Least Two Points|Phase 2 - Percentage of Improved Subjects in Dyspnea Severity, Assessed by Liker Scale|Phase 2 - Change From Baseline in Dyspnea Severity, Assessed by VAS Scale|Changes From Baseline in Body Temperature to Any Post-baseline Timepoints|Phase 2 - Percentage of Subjects Worsened, During Supplemental Oxygen Treatment, From Randomization According to PaO2/FiO2|Phase 2 - Percentage of Subjects Worsened, During Supplemental Oxygen Treatment, From Randomization According to Oxygen Delivery System Classification|Phase 2 - Oxygen Cumulative Duration During the Study|Phase 2 - Oxygen Cumulative Quantity During the Study|Phase 2 - Percentage of Subjects Requiring Mechanical Ventilation Use, Overall|Phase 2 - Cumulative Duration of Mechanical Ventilation Use, Overall|Phase 2 - Percentage of Subjects With Intensive Care Unit (ICU) Admission Need|Phase 2 - Cumulative ICU Stay|Phase 2 - Lung Damage Extension by Severity and by Timepoint|Phase 2 - Lung Exudation by Severity and by Timepoint|Phase 2 - Change From Baseline in Partial Arterial Oxygen Pressure (PaO2)|Phase 2 - Change From Baseline in Oxygen Saturation (SpO2)|Phase 2 - Partial Arterial Oxygen Pressure (PaO2) to Fraction of Inspiration O2 (FiO2) Ratio [PaO2/FiO2 Ratio]|Phase 2 - Change From Baseline in Reactive Protein (CRP)","Dompé Farmaceutici S.p.A","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REPAVID-19|2020-001645-40","May 5, 2020","November 27, 2020","February 2, 2021","March 12, 2021","March 17, 2022","May 24, 2022","Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo, São Paulo, Brazil|Ospedale San Paolo, Milan, Lombardy, Italy|Ospedale San Raffaele, Milan, Lombardy, Italy|Ospedale di Varese, Varese, Lombardy, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04794803/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04794803/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04794803"
50,"NCT04871815","Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.",,"Completed","Has Results","Long COVID","Drug: sodium pyruvate nasal spray","Change in the Symptoms of Long COVID-19 Patients|Change in Body Temperature in Long COVID-19 Patients|Change in Pulse Rate in Long COVID-19 Patients|Change in Blood Oxygenation in Long COVID-19 Patients","Cellular Sciences, inc.|Missouri State University|Dynamic DNA Labs|Trinity Health Care|Family First Medical Research Center","All","18 Years to 40 Years   (Adult)","Phase 2|Phase 3","22","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSI-COVID-19_009","April 27, 2021","March 7, 2022","March 7, 2022","May 4, 2021","October 7, 2021","March 9, 2022","Missouri State University, Springfield, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT04871815/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT04871815/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04871815"
51,"NCT04328961","Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)",,"Completed","Has Results","COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV-2","Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection|The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection|Rate of Participant-reported Adverse Events|Number of Participants Who Had COVID-19 Disease","University of Washington|Bill and Melinda Gates Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","943","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","STUDY00009750|INV-016204","March 31, 2020","September 24, 2020","October 8, 2020","April 1, 2020","December 16, 2021","December 16, 2021","University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04328961/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04328961/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04328961"
52,"NCT04356937","Efficacy of Tocilizumab on Patients With COVID-19",,"Completed","Has Results","SARS-CoV 2","Drug: Tocilizumab|Drug: Placebos","Mechanical Ventilation or Death|Clinical Worsening on Ordinal Scale|Discontinuation of Supplemental Oxygen Among Patients Receiving it at Baseline","Massachusetts General Hospital|Genentech, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","243","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2020P001159","April 20, 2020","July 13, 2020","August 27, 2020","April 22, 2020","July 27, 2021","July 27, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT04356937/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT04356937/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04356937"
53,"NCT04327388","Sarilumab COVID-19",,"Completed","Has Results","Corona Virus Infection","Drug: Sarilumab SAR153191|Drug: Placebo","Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points|Percentage of Participants Who Were Alive at Day 29|Percentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29|Change From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score|Time to Resolution of Fever|Time to Resolution of Fever and Improvement in Oxygenation|Number of Days With Fever|Percentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29|Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours|Change From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2|Time-to-improvement in Oxygenation|Percentage of Participants Alive Off Supplemental Oxygen at Day 29|Percentage of Days With Hypoxemia|Percentage of Days With Supplemental Oxygen Use|Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute|Time to Oxygen Saturation >= 94% on Room Air|Mean Number of Ventilator Free Days|Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula|Percentage of Participants Who Required Rescue Medication|Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study|Number of Days of Hospitalization Among Survivors (Alive Participants)|Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)|Number of Participants With Major or Opportunistic Bacterial or Fungal Infections|Number of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection|Number of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16844|2020-001162-12|U1111-1249-6021","March 28, 2020","July 31, 2020","September 2, 2020","March 31, 2020","May 13, 2021","March 17, 2022","Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 0760004, São José Do Rio Preto, Brazil|Investigational Site Number 0760005, São Paulo, Brazil|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240004, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520001, Talca, Chile|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, Köln, Germany|Investigational Site Number 2760001, Münster, Germany|Investigational site number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Iruma-Gun, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04327388/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04327388/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04327388"
54,"NCT04422561","Prophylactic Ivermectin in COVID-19 Contacts",,"Completed","Has Results","COVID","Drug: Ivermectin Tablets","Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)|Development of COVID","Zagazig University","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","340","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ZU-IRB#6150/31-5-2020","May 31, 2020","July 14, 2020","July 27, 2020","June 9, 2020","August 27, 2020","August 27, 2020","Zagazig University, Zagazig, Sharkia, Egypt","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04422561"
55,"NCT04382924","Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease",,"Completed","Has Results","COVID","Drug: NP-120 (Ifenprodil)","Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients:|Status on an Ordinal Scale Assessed Daily While Hospitalized and on Days 15 and 28 in IP Versus Control Group Patients|NEWS Assessed Days 3, 5, 8 ,11 Daily While Hospitalized and on Days 15 and 29 in IP Versus Control Group Patients|Rate of Mechanical Ventilation in IP Versus Control Group Patients|Duration of Mechanical Ventilation (if Applicable) in IP Versus Control Group Patients|Duration of Supplemental Oxygen in IP Versus Control Group Patients|Time to Return to Room Pressure (SpO2 > 94%) on Room Air|Duration in ICU (if Applicable) in IP Versus Control Group Patients|Rate of Mortality in IP Versus Control Group Patients|Duration of Hospitalization in IP Versus Control Group Patients|Time to Discharge in IP Versus Control Group Patients|Effect on the Rate of Change of Partial Pressure of Oxygen (PaO2) and PaO2/FiO2 Ratio Taken at Baseline and Measured Once Daily up to 2 Weeks of Treatment in IP Versus Control Group Patients","Algernon Pharmaceuticals|Novotech (Australia)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","168","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGN120-3","August 5, 2020","December 24, 2020","January 26, 2021","May 11, 2020","December 3, 2021","December 3, 2021","Westchester Research Center, Miami, Florida, United States|Affinity Health - Loretto Hospital, Chicago, Illinois, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Promedica Health: Toledo Hospital and BayPark Hospital, Toledo, Ohio, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Makati Medical Center, Manila, Philippines|Philippine General Hospital, Manila, Philippines|Lung Center of the Philippines, Quezon City, Philippines|National Institute of Infectious Diseases, Bucharest, Romania","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04382924/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04382924/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04382924"
56,"NCT04324021","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.",,"Terminated","Has Results","SARS-CoV-2","Biological: Emapalumab|Biological: Anakinra","Number of Participants With Treatment Success|Number of Participants Requiring Mechanical Ventilation|Change From Baseline in Modified Early Warning System Score|Change From Baseline in Ferritin|Change From Baseline in Lactate Dehydrogenase (LDH)|Change From Baseline in D-dimers|Change From Baseline in Resting Peripheral Capillary Oxygen Saturation (SpO2)|Change From Baseline in Oxygen Supplementation|Change From Baseline in Partial Pressure of Oxygen/Fraction of Inspired Oxygen (PaO2/FiO2)|Number of Participants With Changes in High-resolution Computed Tomography (CT) Scan of the Chest|Overall Survival|Number of Patients With Hospital Discharge|Change of Carbon Dioxide Tension (pCO2) in Hemogasanalysis From Baseline|Change of Oxygen Tension (pO2) in Hemogasanalysis From Baseline|Change of Potassium in Hemogasanalysis From Baseline|Change of Sodium in Hemogasanalysis From Baseline|Change of Chloride in Hemogasanalysis From Baseline|Change of Lactic Acid in Hemogasanalysis From Baseline|Change of Hemoglobin in Hemogasanalysis From Baseline|Change From Baseline in White Blood Cells With Differential Counts|Change From Baseline in Red Blood Counts|Change From Baseline in Hemoglobin|Change From Baseline in Platelet Count|Change From Baseline in Fibrinogen|Change From Baseline in Complement Factors C3/C4|Change From Baseline in Prothrombin Time|Change From Baseline in Cardiac Troponin|Change From Baseline in Aspartate Aminotransferase (AST)|Change From Baseline in Alanine Aminotransferase (ALT)|Change From Baseline in Total Bilirubin Levels|Change From Baseline in C-Reactive Protein|Change From Baseline in Creatinine","Swedish Orphan Biovitrum","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sobi.IMMUNO-101|2020-001167-93","April 2, 2020","November 13, 2020","November 13, 2020","March 27, 2020","March 10, 2022","March 10, 2022","Regions hospital, Saint Paul, Minnesota, United States|The Valley hospital, Ridgewood, New Jersey, United States|NewYork-Presbyterian Queens, Flushing, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Utah Health, Salt Lake City, Utah, United States|ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|S.C. Malattie Infettive, Ospedale Galliera, Genova, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Dipartimento di Medicina - DIMED, Azienda Ospedale - Università Padova, Padova, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy|ASL Città di Torino, Unit of Infectious Diseases, Medicine, Rheumatology, Torino, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT04324021/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT04324021/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04324021"
57,"NCT04328467","Pre-exposure Prophylaxis for SARS-Coronavirus-2",,"Completed","Has Results","COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome","Drug: Hydroxychloroquine|Other: Placebo","COVID-19-free Survival|Number of Confirmed SARS-CoV-2 Detection|Incidence of Possible COVID-19 Symptoms|Incidence of All-cause Study Medicine Discontinuation|Ordinal Scale of COVID-19 Disease Maximum Severity if COVID-19 Diagnosed at Study End|Incidence of Hospitalization for COVID-19 or Death|Incidence of Possible Study Medication-related Side Effects","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 3","1483","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MED-2020-28720","April 6, 2020","July 13, 2020","July 13, 2020","March 31, 2020","June 30, 2021","July 2, 2021","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04328467/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04328467/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04328467"
58,"NCT04308668","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","COVID-19 PEP","Completed","Has Results","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections","Drug: Hydroxychloroquine|Other: Placebo","Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline|Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline|Rate of Hospitalization|Rate of Death|Rate of Confirmed SARS-CoV-2 Detection|Occurrence of Symptoms Compatible With COVID-19 (Possible Disease)|Rate of All-Cause Study Medicine Discontinuation or Withdrawal|Overall Symptom Severity at 5 and 14 Days|Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry","University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta","All","18 Years and older   (Adult, Older Adult)","Phase 3","1312","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MED-2020-28673","March 17, 2020","May 20, 2020","May 20, 2020","March 16, 2020","May 13, 2021","May 13, 2021","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04308668"
